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Metal-polymer nanocomposites consisting of gold nanorods and temperature-
responsive hydrogel nanoparticulates were investigated for use in externally-controlled 
drug delivery systems.  Several different thermo-responsive hydrogels including poly(N-
isopropyl acrylamide) (PNIPAAm) and poly(N-isopropryl acrylamide-co-acrylic acid) 
(P(NIPAAm-co-AA)) nanoparticles were synthesized for these nanocomposites using an 
aqueous dispersion polymerization method.  In addition, nanoparticles of 
interpenetrating polymer networks (IPN) composed of poly(acrylamide) (PAAm) and 
poly(acrylic acid) (PAA) were synthesized using a water-in-oil emulsion polymerization.  
Temperature-responsive equilibrium swelling behavior of nanoparticles with varying 
crosslinking densities was characterized using dynamic light scattering.  IPN systems 
 vii 
exhibited a positive swelling response upon heating while PNIPAAm and copolymer 
systems collapsed upon increase in temperature above the transition point.  
Nanoparticles were characterized using scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM) which demonstrated shape and morphology of 
polymer particles. 
Gold-polymer nanocomposites were formed by grafting gold nanorods to the 
surface of the polymer nanoparticles.  Amine-functionalized gold nanorods were 
coupled to polymers using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC) and N-hydroxysulfosuccinimide (Sulfo-NHS) to activate carboxyl 
groups on the surface of the polymer nanoparticles.  TEM confirmed successful 
formation of the metal-polymer nanocomposites.   
Loading and release of a model therapeutic were done to assess the potential 
use of the polymer component of the nanocomposite for drug delivery.   Fluorescein, a 
model for chemotherapeutics, was loaded into P(NIPAAm-co-AA) polymer 
nanoparticulates.  Loading of the compound was shown to be a function of crosslinking 
density in the polymer network.  Maximum loading was achieved using nanoparticles 
synthesized with a 10 mol% crosslinker feed ratio with entrapment efficiencies of 80.0 % 
and loading capacities of 12.0 %.  Cytotoxicity studies were performed using a NIH/3T3 
mouse fibroblast cell model.  Cell viabilities in presence of P(NIPAAm-co-AA) 
nanoparticles were comparable to (not statistically different than) controls at 
 viii 
concentrations up to 4 mg/ml.  Similarly, gold-polymer composite concentrations up to 
0.5 mg/ml caused limited cell death. 
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Chapter 1:  Introduction 
In recent years, there has been interest in developing more efficient therapeutic 
systems that can provide highly effective therapy at a disease site while minimizing 
systemic effects.  The goal is to improve the effectiveness of treatment while reducing 
any adverse effects associated with a therapeutic or drug, thereby improving overall 
patient quality of life.  Targeted delivery systems involve the use of a carrier system that 
is capable of delivering a therapeutic in a preferential manner to a disease site.  
Externally controlled also sometimes referred to as remotely triggered delivery systems 
have the potential to go one step beyond standard targeted systems.  In these types of 
systems, a therapeutic can be triggered to release at a specified time and location using 
some non-invasive external stimulus.  Past work has shown that ultrasound, radio 
frequency pulses, magnetic fields, and light may be used to trigger delivery [1-6]. 
This thesis focuses on the development of nanoscale externally controlled 
therapeutic systems for the delivery of chemotherapeutics for breast cancer treatment.  
These systems will respond to exposure to a near infrared (NIR) light source to release 
an entrapped therapeutic.  Light in the NIR range is of interest because of its ability to 
penetrate deeply through tissue compared to light in other wavelength ranges.  Gold 
nanorods that are capable of adsorbing light in this region and converting it to heat will 
serve as a transducer to convert light to a drug release signal.  The gold nanorods heat 
an adjacent thermally responsive polymer nanoparticle that undergoes a volume 
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swelling change in upon heating in an aqueous environment.  This volume change leads 
to a subsequent release of the entrapped therapeutic.  In this manner, a light signal can 
be externally applied to release the therapeutic at a desired time and location. 
Cancer is a group of diseases that lead to uncontrolled, rapid growth of cells in 
the body typically leading to formation of a tumor often invading surrounding tissues 
and in some cases metastasizing, spreading to different areas of the body through blood 
or the lymphatic system.  Overall, cancer is the fourth leading cause of death following 
cardiovascular disease, infectious diseases, and ischemic heart disease.  Approximately 
13% of all deaths worldwide each year are caused by various types of cancer [7, 8]. 
Breast cancer affects nearly 200,000 new women in the United States each year, 
leading to over 40,000 deaths per year.  This disease is the second leading cause of 
cancer death and makes up 10% of all cancers among women in the United States.  
Chemotherapy is one of the primary treatments used among patients with breast cancer 
and important for both pre and postoperative therapies.  Chemotherapeutic agents 
which are typically delivered systemically via either an oral or intravenous route most 
commonly work by disrupting cell growth in rapidly dividing cells.  The systemic delivery 
of these agents leads to a number of adverse effects including nausea, vomiting, hair 
loss, cardiotoxicity, and immunosuppression [9, 10].  Limiting delivery of 
chemotherapeutics to the disease location may improve therapeutic efficacy while 
minimizing adverse health effects. 
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The drug carrier systems proposed in this thesis consist of temperature 
responsive polymer hydrogel nanoparticles that exhibit a swelling transition upon 
heating through a transition temperature range, with gold nanorods grafted to the 
polymer nanoparticles that are capable of absorbing light and transmitting heat to the 
polymer.  The heating triggers a swelling response in the carrier and an associated 
release of a therapeutic.  Nanoscale systems are of interest because they could be 
administered intravenously, localize at a disease site because of the enhanced 
permeability and retention (EPR) effect and have extended circulation half-lives. 
Towards the development of these systems, temperature responsive nanogels 
were synthesized and their swelling behavior as a function of temperature was 
characterized.  Chapter 3 describes emulsion and precipitation polymerization methods 
that were used to synthesize these materials.  Dynamic light scattering measurements 
were used to measure the hydrodynamic diameter of the particles and quantify 
equilibrium swelling behavior.  Properties of the materials such as incorporation of 
comonomers or extent of crosslinking were evaluated for their effect on temperature 
responsive behavior. 
The addition of the gold nanorods to form gold-polymer composites is described 
in Chapter 4.  Gold nanorods were grafted to the surface of polymer nanoparticles using 
a condensation reaction between amine-functionalized gold nanorods and carboxyl 
groups present in the polymer and characterized using transmission electron 
microscopy (TEM). Absorption spectra collected over the transition temperature range 
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indicated that as polymer nanoparticles collapsed the attached gold nanorods were 
drawn closer together causing plasmon coupling and an associated change in the 
absorbance spectrum. 
The potential use as chemotherapeutic drug delivery systems was investigated 
using a model therapeutic, fluorescein, often as a model for cancer drugs such as 
doxorubicin.  The model drug was loaded into polymer nanoparticles and results are 
quantified in Chapter 6.  Release of the compound from the nanogels was also 
measured and characterized in Chapter 6. 
In order to evaluate the potential of this system to be used in vivo as a 
therapeutic carrier and diagnostic tool, cellular toxicity and light-triggered swelling were 
investigated in Chapter 7.  Cell viability studies demonstrate the potential 
biocompatibility of the nanoparticle systems.  A swelling response was also shown to be 
induced in the gold-polymer composites in response to light.  A photoacoustic signal 
was detected from the composite nanoparticles demonstrating the ability of the 
particles to act as a contrast agent in certain medical imaging techniques.  The final 
chapter will discuss the conclusions that have been drawn from the results of this thesis 
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Chapter 2:  BACKGROUND 
In an effort to improve patient treatment and overall quality of life, recent work 
in biomaterials has sought to develop systems that can increase effective dosing while 
simultaneously decreasing adverse side effects that occur as a result of therapeutic 
administration.   
Targeted drug delivery has been widely studied as a method of delivering a 
therapeutic to a localized disease site such as a tumor or a site of inflammation while 
minimizing the distribution of the drug to other parts of the body.  The ability to 
concentrate therapeutic delivery at the disease site is advantageous over traditional 
systemic delivery because it may increase therapy at the disease site while decreasing 
the overall necessary dose and lessening the severity of adverse side effects.   
Externally controlled or triggered delivery systems have been developed to 
specify both the time and location of therapeutic delivery. Externally controlled 
therapeutic systems are devices that can be triggered to release a therapeutic at a 
desired time and location, by external means.   These systems release a therapeutic 
agent in response to triggering mechanisms such as ultrasound waves [1-3], light [4], 
magnetic field [5, 6], or other methods that can be used to transmit a signal to a delivery 
system in vivo.  Metal nanoparticles can act as the signal receiver in light triggered 
systems because of their ability to convert light into heat. When coupled with a 
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temperature sensitive polymer, metal nanoparticles can trigger release of a drug as by 
causing a swelling transition in the polymer through heating. 
Nanoscale devices are desirable for drug delivery systems because they more 
readily localize at tumor sites as a result of the enhanced permeability and retention 
(EPR) effect.  Nanoparticles have improved circulation half-lives in the bloodstream and 
collect in tumor microvasculature with poor lymphatic drainage [7].  Nanoscale 
materials are essential for the development of injectable targeted and externally-
triggered delivery systems. 
This chapter discusses the motivation and methods behind the different 
strategies for targeted delivery for cancer treatment focusing on breast cancer. A short 
discussion of past work in polymer nanoparticles for drug delivery and background on 
the use of metal nanoparticles for biomedical applications will follow.  Additionally, past 
successes in the area of externally controlled devices will be summarized.  Use of gold 
nanoparticles as contrast agents in photoacoustic techniques for medical imaging will 
also be discussed. The conclusion of the chapter will summarize the motivation and 
aspects involved in the development of nanoscale externally-controlled systems.  
2.1 BREAST CANCER 
Cancer is a group of diseases that lead to uncontrolled, rapid growth of cells in 
the body typically leading to formation of a tumor often invading surrounding tissues 
and in some cases metastasizing, spreading to different areas of the body through blood 
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or the lymphatic system.  Overall, cancer is the fourth leading cause of death following 
cardiovascular disease, infectious diseases, and eschemic heart disease.  Approximately 
13% of all deaths worldwide each year are caused by various types of cancer [8-10]. 
Breast cancer is a type of cancer that originates in one of several areas in breast 
tissue.  Most commonly the cancer begins in either the lobules which are glands for the 
production of milk or in the ducts that connect the lobules to the nipple, known as 
ductal carcinomas and lobular carcinomas respectively.  Cancers that stay confined to 
these sites are known as in situ carcinomas, but most of the cancerous tumors that 
begin in the ducts or lobules will become invasive cancers that spread to the 
surrounding fatty, connective, or lymphatic tissue in the breast.  In situ cancers are 
almost fully curable, while invasive cancers have varying negative effects depending on 
their extent of growth before diagnosis [11, 12].  
The extent of the growth and spread of a breast cancer is typically quantified by 
classification into one of five different stages.   Determination of the malignant stage is 
based on the TNM classification system: size of tumor (T), involvement of lymph nodes 
(N), and distant metastasis (M).  Stage 0 is a pre-cancerous disease or marker such as an 
in situ carcinoma.  Stage I is an early stage cancer referring to a small localized invasive 
tumor, typically less than 2 cm in diameter in the case of breast cancer.  Cancers 
classified as Stage II are larger and more advanced.  Breast cancers classified as Stage II 
are generally at least 2-5 cm in diameter and/or there is spread of cancerous cells to the 
lymph nodes.  Stage III cancers are larger still and have in all cases spread to the lymph 
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nodes.  Breast cancers at Stage III may have also spread to the skin on the breast or to 
the chest wall.   Stage IV cancers are metastatic meaning cancerous cells have spread to 
other organs of the body.  Stage I-III cancers are considered early stage cancers and 
potentially curable through treatment, while metastasized Stage IV cancer is typically 
incurable but may be treated [13]. 
Each year approximately 190,000 women in the United States are diagnosed 
with breast cancer.  In 2006 40,820 women died from breast cancer in the United States 
making it the second leading cause of cancer death among women, making up over 10% 
of all cancer incidences among women in the United States [8, 9, 14].  Additionally, the 
disease affects a small number of men in the United States with approximately 1900 
incidences per year causing over 400 deaths.  Worldwide, breast cancer leads to over 
500,000 deaths per year [10]. 
Primary methods of treatment of Stage I-III breast cancers include surgery, 
radiation therapy, and systemic therapies such as chemotherapy, biologic treatments, 
and hormone treatments.  Most individuals who are diagnosed with an invasive breast 
cancer will have a surgery to remove the cancer from the breast accompanied by one or 
more of the other therapies to shrink the tumor, eliminate cancerous tissue following 
surgery, or to prevent recurrence[11-13].   
Surgical removal of the cancerous tissue may consist of a lumpectomy, where 
only the tumor plus a small surrounding area of normal tissue is removed, or a 
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mastectomy which is removal of the entire breast.  Frequently, lymph nodes are also 
removed during surgery to determine the extent of spread of the disease [12]. 
Radiation therapies used for breast cancer are typically applied using an external 
radiation source that is targeted at the affected breast to kill cancer cells.  Radiation 
therapies may be used prior to surgery to reduce the size of the tumor or following 
surgery to eliminate remaining cancerous tissue.  External radiation is almost always 
used for a period of 5-7 weeks following a lumpectomy [11]. 
Anti-cancer drugs are often delivered systemically through the oral delivery 
route or intravenous injection.  When these drugs are administered prior to surgery, it is 
known as neoadjuvant therapy, with the goal typically being to shrink the tumor enough 
to allow for easier removal during lumpectomy.  Adjuvant therapy consists of drugs 
adminstered following the removal of a tumor to eliminate cancer cells that may have 
migrated to the lymph nodes or other parts of the body [12]. 
Certain biologics administered systemically have been shown to minimize cancer 
growth.  Monoclonal antibodies such as herceptin target the human epidermal growth 
factor receptor 2 (HER2).  HER2 overexpression in breast cancers has been shown to be 
associated with faster growing, more aggressive tumors.  The drugs can be used to 
minimize the HER2 effect [15].  Another monoclonal antibody, bevacizumab, blocks 
vascular endothelial growth factor A thereby minimizing growth of new blood vessels 
and slowing tumor growth [16]. 
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Because hormones such as estrogen have been shown to promote breast cancer 
growth, drugs may be administered to control the production of estrogen or to block 
the effects of the hormone.  Tamoxifen is commonly administered to minimize the 
effects of estrogen.  Several other drugs known as aromatase inhibitors can be effective 
in minimizing the production of estrogen in postmenopausal women [17]. 
Chemotherapeutic drugs are a broad class of therapeutics that target fast-
dividing cells, by either impairing cell division or causing actual cell death.  Neoadjuvant 
treatments help to shrink the tumor prior to resection, while adjuvant treatments can 
treat remaining cancer cells and prevent resection.  In later stage cancers that cannot be 
entirely removed or in the case of metastatic cancers chemotherapies are often applied 
to minimize further spread of the tumor with the goal of extending lifespan [17-19]. 
2.2 CHEMOTHERAPY  
Anticancer drugs known as chemotherapeutics are administered systemically to 
around 75% of all cancer patients via either an oral or intravenous route.  
Chemotherapeutics may be used in all stages of breast cancer and delivered either 
preoperatively or postoperatively [18].  Preoperative or neoadjuvant delivery can help 
to shrink the tumor allowing for easier and more total lumpectomy while adjuvant 
therapy following operation is used to prevent recurrence and to eliminate cancer cells 
that may be in the lymph nodes or other parts of the body.  For nearly all Stage 3 breast 
cancers and many Stage 2 invasive breast cancers, neoadjuvant therapy is the standard 
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treatment and has been shown to allow for increased removal of locally advanced 
tumors [20]. 
There are a number of different chemotherapeutic drugs that are administered 
to breast cancer patients, and frequently these drugs are administered together in 
combinations of 2-4 of the different types of drugs.  The most common classes of 
chemotherapeutic drugs used to treat breast cancer are alkylating agents, 
antimetabolites, anthracyclines, and taxanes [18]. 
Alkylating agents such as cyclophosphamide work by effectively crosslinking DNA 
strands thereby preventing cell division and tumor growth.  The alkylating agents 
alkylate guanine bases in DNA, and because of the fast dividing nature of cancer cells, 
they are susceptible to this modification.  Side effects for cyclophosphamide tend to be 
less severe than for many other chemotherapeutics, but some side effects do commonly 
occur including nausea and vomiting, hair loss, diarrhea, and joint pain [17]. 
Antimetabolites used in chemotherapy typically mimic the structure of either 
purine or pyrimidine.  The pyrimidine analog fluorouracil (5-FU) is the most common 
antimetabolite used to treat breast cancer.  5-FU blocks DNA replication by acting as a 
thymidylate synthase inhibitor preventing synthesis of pyridimine thymidine which is 
necessary for replication [21].  Antimetobolites affect all DNA replication and cell 
growth, most pronounced in any fast dividing cells.  Because of their far reaching 
effects, they may have severe side effects such as bone marrow suppression, digestive 
tract inflammation, dermatitis, diarrhea, and hair loss.  Additionally, individuals with a 
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condition known as dihydropyrimidine dehydrogenase deficiency (DPD deficiency) are 
unable to metabolize pyrimidine based drugs and for these patients 5-FU treatment can 
be lethal. 
Anthracyclines are another class of drugs that inhibits the growth of cancer cells.  
Doxorubicin (adriamycin) is used most commonly in breast cancer chemotherapeutic 
regimens.  Anthracylines, such as doxorubicin, are administered intravenously and 
inhibit replication by intercalating DNA.  Doxorubicin is a very versatile drug used to 
treat a wide range of cancers including breast cancer.  The positive effects of 
doxorubicin are accompanied by a number of adverse effects.  Cardiotoxicity is a major 
concern for patients who are treated with antracyclines, and high doses can lead to a 
number of heart related conditions including heart arrhythmias, cardiomyopathy, heart 
failure, and the possibility of death.  Other common side effects include nausea, 
vomiting, and total hair loss [19].   
To reduce the side effects of doxorubicin, systems have been developed to 
enhance localization of the drug at the target cancer site and decrease systemic effects. 
Pegylated liposomal doxorubicin systems including Doxil and Caelyx have been shown to 
increase the therapeutic index of doxorubicin.  Pegylation inhibits uptake by the 
reticulo-endothelial system (RES) increasing the half-life of circulation as well as 
increasing extravasation into the leaky vasculature of tumors.  The liposomal systems 
have been shown to increase concentration of drug or radio tracers at tumor sites.  
Decreased cardiotoxicity has been observed in patients treated with pegylated 
 14 
liposomal doxorubicin compared to free drug [22, 23].  A non-pegylated liposomal 
formulation, Myocet, has shown antitumor activity comparable to free doxorubicin 
while decreasing cardiotoxicity in treatment of metastatic breast cancer patients [24, 
25].  Myocet has been approved for treatment of breast cancer in Europe and Canada, 
but it has not yet been approved by the FDA in the United States.   
2.3 TARGETED DRUG DELIVERY 
The targeting of drug delivery systems, most commonly micro- and nanoscale 
particles provides more efficient treatment and improves quality of life for patients by 
minimizing potential adverse effects.   In a perfect targeted system, the entire drug 
payload of all carriers would be delivered at the preferential site.  In this case, the 
dosage can be tailored to have the most significant effect at the disease site without 
causing systemic adverse affects.  Externally-triggered devices seek to go a step beyond 
simple targeting as release of drug is only triggered at the site where treatment is 
desired at a specific point in time. 
 Nanoparticles are desirable in many targeted delivery systems because their 
properties allow them to circulate in the bloodstream for extended periods of time and 
they have a high level of accumulation at tumor sites.  Delivery of anticancer drugs to 
tumor sites is the most commonly investigated use of targeted nanoparticles to date.  
Intravenously administered nanoparticles under the size of 200 nm have been shown to 
circulate much longer than systems larger than this size, because of their ability to 
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escape the body’s natural defense mechanisms such as the RES [26]. These carriers are 
also the right size to take advantage of the enhanced permeability and retention (EPR) 
effect.  Particles smaller than 400 nm have been shown to extravasate leaky tumor 
vasculature via the EPR effect, and those smaller than 200 nm may be even more 
effective [27].   
While the EPR effect is an example of passive targeting, taking advantage of 
properties of the drug or carrier to localize at the target site, active targeting involves 
the incorporation of molecules in the delivery system that are intended to interact with 
the physiological target.  Typically a targeting ligand is adhered to the surface of the 
nanoparticle or covalently attached.  The addition of targeting ligands has been shown 
to improve the therapeutic effect of delivery systems both in vitro and in vivo [28, 29]. 
Folate receptor is a glycoprotein that has frequently been observed to have 
elevated expression in tumors while it is not present in most normal tissues making it a 
very attractive candidate for targeted anticancer delivery [30].   Nanoparticles 
functionalized with folate, the receptor target, have been shown to have higher 
therapeutic efficacies in the treatment of tumors than nontargeted nanoparticles in 
both in vitro and in vivo models [28].   
Another common ligand used to target delivery systems to tumors is transferrin.  
The transferrin receptor (TfR) has been shown to be expressed at higher levels on 
cancer cells than on normal cells, so nanoparticle systems have been designed to target 
cancer cells by attaching transferrin to the delivery system [29].  Improvements in 
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delivery and associated cancer cell death have been observed using transferrin-
functionalized systems [31].  Several studies have shown that the tumor accumulation is 
similar when comparing systems incorporating transferrin and their nontargeted 
counterparts [32].  The improved delivery has therefore been attributed to increased 
tumor cell internalization of the nontargeted nanoparticles. 
Several systems have been developed to use monoclonal antibodies to target 
cancerous tumors.  An anti-HER2 monoclonal antibody has been incorporated into 
doxorubicin loaded liposomes and shown to increase antitumor efficacy over control 
doxorubicin formulations [33].  Other studies have demonstrated that targeted 
liposomes with the anti-HER2 antibody were found at high concentrations in tumor cells 
while nontargeted liposomes where more commonly in the extracellular spaces.  
Additionally, targeted liposomes had a much greater preference for tumor cells over 
host cells while control systems showed no preference [34]. 
Another monoclonal antibody, 2C5, has been shown to increase efficacy when 
incorporated into liposomal doxorubicin systems.  The targeted systems showed 
increased accumulation in lung cancer models when compared to nontargeted 
liposomal systems.  The measured tumor reduction was also shown to be higher for the 
targeted systems compared to the control [35]. 
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2.4 POLYMER NANOPARTICLES 
Particles that measure less than 0.1 μm in diameter are defined as nanoparticles.  
In practice, polymer particles smaller than 1 micron are commonly referred to as 
nanoparticles, and in this thesis they will be referred to as such.   Polymer nanoparticles 
are of interest for applications in drug delivery because of their potential to target a 
variety of different specific locations in the body, elongate periods of dosage, protect 
sensitive therapeutics such as proteins, increase half-life circulation, and reduce 
systemic effects [36, 37].  Polymer nanoparticles with many different types of properties 
have been developed for use in drug delivery systems including biodegradable systems, 
hydrogel systems, and self-assembled systems such as micelles, liposomes, and 
polymersomes. 
The use of polymer nanoparticles is particularly advantageous in drug delivery 
because of their inherent potential to avoid the RES and take advantage of the EPR 
effect [38, 39].  Microparticles or large nanoparticles are rapidly recognized by 
macrophages and cleared by the RES through the liver and spleen.  Nanoparticles 
measuring less than 300 nm in diameter show increased avoidance of the RES 
particularly in particles that are less than 100 nm in diameter.  This avoidance of the RES 
leads to a longer circulation half-life and ultimately greater localization at the delivery 
site.  Because of the fast growth of tumors, the vasculature tends to be leaky and 
lymphatic drainage poor.  Nanoparticles are preferentially extravasated and 
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concentrated at these tumor cites while small molecular weight drugs are not retained 
at such high concentrations. 
Primarily, polymer nanoparticles are formed by one of two broad methods, 
either the dispersion of preformed polymers into nanoparticles, or monomer 
polymerization designed to directly polymerize into the final particle form.  Additionally, 
block copolymers have been synthesized in order to assemble nanoscale polymersomes 
or micelles.  These polymer nanoparticles along with various block copolymer 
assemblies have been extensively investigated for use as drug carriers [40, 41]. 
2.4.1 Biodegradable Systems 
Biodegradable nanoparticle systems are of interest for the ability to combine 
desirable nanoscale properties with enhanced biocompatibility and controlled release.  
The most widely investigated biodegradable polymers for nanoparticle delivery are 
those based on the polyesters poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their 
copolymer poly(lactic acid-co-glycolic acid) (PLGA).  By adjusting the ratio of lactic acid 
to glycolic acid in PLGA the rate of degradation can be controlled.  Increased lactic acid 
content extends the degradation time of the polymer.  The polymer degrades by 
hydrolysis to the monomers lactic acid and glycolic acid which can be metabolized by 
the body.  Because the degradation time of PLGA can be easily tuned and the 
biocompatibility of the system has led to FDA approval for resorbable sutures, a large 
number of PLGA nanoparticle delivery systems have been developed. 
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Biodegradable polymer nanoparticles are formed most commonly using 
emulsion and solvent evaporation techniques, where the polymer is first dissolved in an 
organic phase that is subsequently dropped into a continuous aqueous phase and 
stirred until the solvent evaporates.  Hydrophobic drugs can easily be incorporated into 
particles during this process by solvating the drug along with the polymer in the organic 
phase.  These oil-in-water emulsions have been used to load a variety of hydrophobic 
drugs, such as anti-cancer therapeutics [42-44].  In addition to hydrophobic drugs, 
encapsulation of water-soluble drugs and biomolecules, including proteins and certain 
chemotherapeutics, has been achieved with water-in-oil-in-water double emulsion 
techniques [45-47].  
Other synthesis techniques, such as nanoprecipitation and spray drying have also 
been used effectively to produce PLGA nanoparticles loaded with therapeutics [48].  In 
traditional spray-drying, the polymer is dissolved in a volatile solvent and the solution in 
sprayed into an apparatus where the particles are formed as the solvent evaporates 
[49].  Typically, this method yields particles at the upper limit of the nanoscale and in 
the microscale.   
A modification of this method known as spray freezing into liquid (SFL) is also 
used to synthesize polymer micro and nanoparticles.  In this case, a solution of the 
polymer is sprayed through an atomizing nozzle into liquid nitrogen over a solvent such 
as frozen ethanol [50].  Particles form upon contact with the liquid nitrogen and are 
collected in the ethanol after evaporation of the liquid nitrogen.  Drugs have been 
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incorporated during particle formation by addition to polymer solution or formation of 
an oil-in-water emulsion prior to atomization [51, 52].   
Recent studies have carefully evaluated the effects of PLGA nanoparticle 
properties on drug loading.  For example, smaller nanodelivery systems have a smaller 
volume, and therefore, would be expected to have a smaller maximum loading capacity.  
In the majority of studies, the maximum loading capacity is not determined for a carrier.  
The achieved loading capacity of a delivery system is dependent on factors beyond 
volume alone.  For example, drug loading and release from PLGA micro- and 
nanospheres have been shown to be inversely correlated with size.  In a study that 
compared two sizes of PLGA particles, dexamethasone was first loaded into PLGA 
microspheres using a typical oil-in-water solvent evaporation method to produce 20 μm 
particles.  Smaller 1 μm particles loaded with dexamethasone were produced via 
emulsion polymerization. The emulsion polymerization scheme for the smaller particles 
led to a dexamethasone encapsulation efficiency of 11.2% compared to 1% for the 
larger microparticles when incubating 100 mg of dexamethasone with 500 mg of 
polymer [53].   
Drug delivery systems composed of polyanhydrides have been widely 
investigated because of their surface eroding degradation mechanism which can lead to 
near zero-order release profiles [54, 55].  In general, drugs have been successfully 
incorporated in polyanhydride disks such as the Gliadel® system or microparticles [56].   
Double emulsion techniques including water-oil-water, or water-oil-oil have also been 
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used to synthesize biodegradable nanoparticles based on polyanhydrides for drug 
delivery [57]. However, there have been limited studies demonstrating loading and 
release from polyanhydride carriers on the nanoscale.   
In one study, paclitaxel or 2-hydroxypropyl-β-cyclodextrin (HPCD)-complexed 
paclitaxel was encapsulated in polyanhydride nanoparticles composed of poly(methyl 
vinyl ether-co-maleic anhydride) during particle formation using a solvent displacement 
method which simultaneously allowed nanoparticle formation and loading.  Up to a 167 
μg/mg loading capacity was obtained for nanoparticles with an average diameter of 302 
nm.  The controlled release of HPCD-paclitaxel was then demonstrated in different 
simulated biological fluids.  No release was observed from particles in simulated gastric 
fluid (pH 1.2) whereas there was complete release over a 24 hour period in simulated 
intestinal fluid (pH 7.5) [58].   
Like synthetic biodegradable systems, nanodelivery systems composed of 
naturally occurring biodegradable polymers have been investigated for drug delivery.  
Some of the most widely studied are systems based on the biodegradable and 
biocompatible polysaccharide chitosan.  The potential use of chitosan carriers has been 
demonstrated for a vast number of drugs and applications.  For example, chitosan 
carriers have received considerable attention for delivery of nucleic acids due to 
chitosan’s net positive charge.  One of the contributing factors to chitosan’s versatility is 
that a number of techniques have been developed to synthesize chitosan nanoparticles 
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including ionic gelation, precipitation, reverse micelle formation, self-assembly, and 
spray drying [59, 60]. 
In one study examining the use of chitosan for delivery of biomolecules, a model 
protein, bovine serum albumin (BSA), was loaded into chitosan nanoparticles prepared 
by two different methods using tripolyphosphate (TPP) as an ionic crosslinker.  In the 
first method termed “incorporation”, BSA was incorporated into the polymer matrix 
during particle formation by adding BSA to a chitosan solution before the addition of the 
TPP crosslinker at which point particles spontaneously formed during mixing.  Using the 
“incubation” method, BSA was simply adsorbed to the surface of nanoparticles during 
incubation following particle coacervation.  Encapsulation efficiencies up to 88% were 
obtained and BSA release was primarily shown to be a fast release over a 6 hour period 
[61].  In another study, chitosan nanoparticles crosslinked with TPP were loaded with 
methotrexate disodium (MTX) using a post-polymerization incubation method.  Loading 
capacities up to 52% and loading efficiencies up to 78% were obtained when an MTX 
concentration of 1.26 mg/mL was incubated with a 0.16 wt% nanogel solution [62]. 
Chitosan nanoparticles have also been formulated to deliver anticancer drugs. 
For example, a water-in-oil microemulsion method was used to entrap a doxorubicin-
dextran conjugate in chitosan nanoparticles having a hydrodynamic diameter of 100 nm. 
Entrapment efficiencies were measured between 60-65%.  In a mouse model, treatment 
with the loaded nanoparticles led to faster and more complete tumor regression than 
free drug or empty nanoparticles [63].   
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Another natural biodegradable material used to synthesize nanoparticles for 
drug delivery applications is the anionic biopolymer alginate.  Most often calcium 
chloride is added to a solution of alginate to induce ionic crosslinking, resulting in micro- 
and nanoparticle polymer networks. In one case, alginate gelation with calcium ions 
followed by coating with chitosan produced nanoparticles intended for oral insulin 
delivery applications.  A maximum insulin encapsulation efficiency was measured at 92% 
with loading capacities up to 14.3% [64].  Isoniazid, rifampicin, and pyrazinamide were 
encapsulated in alginate particles using a cation gelation method in an effort to design 
aerosolized nanoparticles for treatment of tuberculosis.  Calcium chloride was added to 
sodium alginate solution containing varying amounts of the three drugs to induce the 
gelation and encapsulation of the drug.  Drug encapsulation efficiencies ranged from 70-
90% in particles at the upper limit of so-called nanoparticles with an average size just 
around 1 μm [65]. 
2.4.2 Self-Assembled Systems 
Self-assembled nanoparticles, including liposomes, micelles, and polymersomes, 
can be formed using various amphiphiles such as natural lipids or block copolymers.  
Liposomes are vesicles that consist of a spherical shaped lipid bilayer, or multilayers, 
containing an inner aqueous void space.  Liposomal encapsulation is a versatile method 
to load therapeutics, because hydrophilic drugs and biomolecules can be loaded in the 
inner aqueous void, while hydrophobic molecules can be entrapped in the lipid bilayer.  
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Liposomal delivery of chemotherapeutics has been established as an effective method 
to increase efficacy and decrease toxicity over free drug, evidenced by the success of 
liposomal doxorubicin, Doxil®, which has been approved for human use in cancer 
treatment [66].   
In addition to the lipid structures, synthetic block copolymers built with one 
hydrophilic block and one hydrophobic block have been shown to exhibit a variety of 
self-assembled structures including spherical or cylindrical micelles and vesicles with 
architectures that resemble liposomes known as polymersomes [67].  Micelles, 
nanoparticles with a hydrophobic core and hydrophilic outer layer, self-assembled from 
amphiphilic block copolymers in aqueous media, are frequently used to entrap 
hydrophobic drugs during micelle formation.  During spontaneous micelle formation in 
an aqueous environment, hydrophobic drugs are localized in and around the 
hydrophobic core [68].  This loading method has been used to entrap a variety of 
therapeutics, particularly anticancer agents, in block copolymers of poloxamers, which 
consist of blocks of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), and 
NK105, which consists of blocks of PEG and a modified polyaspartate [41, 69, 70]. 
 Using this method of drug loading, micelle nanoparticles have been used to 
entrap hydrophobic anticancer therapeutics.  Biodegradable, cationic micelle 
nanoparticles were self-assembled using amphiphilic poly, P(MDS-co-CES).  In this study, 
Herceptin®, which is a monoclonal antibody, was attached to the surface of the particles 
while paclitaxel was loaded into the micelles by dissolving the polymer and drug in DMF 
 25 
and dialyzing against a sodium acetate/acetic acid buffer. This method let to 
encapsulation efficiencies of paclitaxel of 58.1% and a loading capacity of 14.3%. 
Release studies demonstrated the that the drug could be released from the 
nanoparticles over a 69 hour period [71].  
While traditional micelle systems have been used primarily to incorporate 
hydrophobic drugs, adapted systems have been used to entrap more hydrophilic species 
such as biomolecules.  For example, drug carrier systems called polyion complex (PIC) 
micelles have been synthesized from PEG block copolymers. The PIC micelles are formed 
using block copolymers consisting of a hydrophilic block and a polyionic block.  In this 
case, electrostatic interactions between the ionic polymer and an oppositely charged 
species are a driving force for the formation of the micelles.  Poly(ethylene glycol-
grafted-chitosan), PEG-g-chitosan, block copolymers were used to entrap diammonium 
glycyrrhizinate (DG) in micelles assembled in acetate buffer after addition of TPP to 
induce chitosan aggregation.  Loading efficiencies of DG over 96% have been obtained 
using these systems and the average diameter of micelles was between 20 and 30 nm.  
Release profiles varied based on the free ions in solution.  In ionic solution, a burst 
release was observed, but there was limited release in DI water [72]. 
Polymer vesicles called polymersomes or polymerosomes have been used to 
entrap a variety of therapeutics and model drugs.  For example, polymersomes with 
diameters around 100 nm were prepared from triblock copolymers, poly(caprolactone)-
poly(ethylene glycol)-poly(caprolactone), PCL-PEG-PCL, using a double emulsion 
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method.  Insulin was incorporated during self-assembly of 122 nm particles [73].  In 
another study, triblock copolymers, poly(ethylene oxide)-b-poly(acrylic acid)-b-poly(N-
isopropylacrylamide) (PEO-PAA-PNIPAM), were synthesized via RAFT polymerization.  
The resulting polymers were water soluble at room temperature, but formed polymer 
vesicles with diameters between 170 and 250 nm above 32° C.  These polymersomes 
were loaded with FITC-dextran during self-assembly at elevated temperatures and then 
crosslinked using cystamine via carbodiimide chemistry.  The crosslinks were shown to 
degrade in the presence of dithiothreitol, and therefore, it was hypothesized that these 
systems are degradable in vitro and in vivo.  Loading capacity of these nanoparticles was 
measured at levels exceeding 85% by weight [74]. 
Recently, there has been interest in creating systems that are hybrid particles 
combining properties of liposomes and synthetic polymer systems for nanodelivery 
applications.  Cationic lipids have been combined with peptide-lipid amphiphiles and 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-carboxy(polyethylene glycol) to 
design liposome nanoparticles targeted to the urokinase plasminogen activator receptor 
(uPAR) overexpressed on many tumors.  The particles have an ABCD structure, an inner 
aqueous (A) layer of loaded anionic nucleic acids, a cationic lipid bilayer (B), a PEG layer 
for stealth characteristics (C), and a peptide sequence layer for targeting of uPAR (D).  
Loading efficiencies as high as 60% were achieved when 10 wt% docetaxel was added 
during the particle self-assembly process [75]. In another example, hybrid systems were 
formed through self-assembly to form nanoparticles with a lipid monolayer surrounding 
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a PLGA core loaded with a hydrophobic drug.  This unique system relied on PEG-
conjugated lecithin to form a hydrophilic outer shell of PEG as the lipid monolayer 
formed around the hydrophobic PLGA polymer.  Drug loading of docetaxel into the PLGA 
core was accomplished during this self-assembly process by first dissolving polymer and 
drug in an organic solvent and then dripping this solution into an aqueous solution 
containing PEG-lecithin.  This process led to the formation of the particles via self-
assembly and the solvent was allowed to evaporate.  Encapsulation efficiencies of 62% 
were obtained using this method when adding 10 wt% docetaxel to the organic polymer 
solution.  Controlled release was observed over a 100 h period and shown to be a 
function of lipid coverage, where the release rate could be slowed by increasing the lipid 
to polymer ratio [76].  
2.4.3 Nanogels 
Upon injection into the bloodstream, nanoscale systems have the ability to 
circulate for extended periods of time and to be taken up by cells. Their dimensional 
properties such as high surface area and rapid response to external stimuli make them 
attractive candidates for in vivo systems [77].  In particular, nanoscale hydrogel systems, 
known as nanogels, are of interest for use as “intelligent” drug carriers.  These 
intelligent materials respond to external stimuli such as pH, temperature, and ionic 
strength by imbibing water and swelling under certain of these conditions.   
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Hydrogels are crosslinked polymers that are hydrophilic but insoluble in aqueous 
environments.  Under specific conditions, the polymer networks imbibe water to swell.  
Hydrogel carriers have been designed to exhibit stimuli-sensitive behavior, where 
degree of swelling is affected by some external stimulus such as pH, temperature, ionic 
strength, or electric field [78, 79]. Because of this swelling behavior in response to their 
environment, stimuli-sensitive polymers are known as “intelligent” or “smart” polymer 
systems.   
Intelligent hydrogel carriers have been used to encapsulate various therapeutic 
molecules and subsequently release them following a change in one of these external 
conditions.  Release from these systems has been triggered by both swelling and 
shrinking of hydrogel carriers [4, 80].  In the first case, a therapeutic molecule is 
encapsulated in a carrier in its collapsed state where the drug is protected and small 
mesh size limits diffusion in or out of the polymer matrix [81].  If the polymer 
encounters an environment that triggers swelling, the mesh size increases, and there is 
an increase in the rate of diffusion, so that the therapeutic is released into the 
surrounding environment.  In the latter case, a polymer is synthesized so that in its 
swollen state the properties are such that the polymer can encapsulate and protect a 
molecule of interest. Upon deswelling or shrinking there is a fast release as some of the 
encapsulated material is squeezed out of the polymer matrix [82].  As this cycle is 
repeated, a pulsatile release of the therapeutic may be observed. 
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Temperature-responsive polymers can exhibit one of two different types of 
temperature behaviors in aqueous solutions and will separately be examined in this 
work.  Both types of these systems, those that exhibit upper critical solution 
temperature (UCST) and those that fall into the class of lower critical solution 
temperature (LCST) behavior will be synthesized and investigated here.  Hydrogels with 
UCST behavior have characteristics such that at lower temperatures some polymer-
polymer interactions lead to a less swollen state.  Upon heating through the UCST these 
interactions are weakened, so that the polymer effectively becomes miscible with the 
aqueous phase, but because the polymer is crosslinked the systems imbibes water and 
swells.   
Certain types of interpenetrating polymer networks, IPNs, such as those based 
on acrylamide (AAm) and acrylic acid (AA) demonstrate this type of behavior with 
transition temperatures near 40 °C [83].  IPNs consist of two separately crosslinked 
polymer networks that are physically entangled with the first network, but not 
covalently attached.  The PAA network and the PAAm network undergo hydrogen 
bonding at low temperatures, which breaks down above the UCST and electrostatic and 
steric interactions cause the polymer to swell. 
Polymers demonstrating LCST behavior, most commonly poly(N-
isopropylacrylamide), PNIPAAm, and related copolymers, have also been investigated 
for use as temperature sensitive drug carriers.  The presence of separate hydrophilic 
and hydrophobic groups in the polymer chain generally leads to this behavior.  At low 
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temperatures, hydrogen bonding interactions between water and the hydrophilic 
groups lead to a swollen state, but an increase in temperature beyond the transition 
temperature leads to a weakening of the water-polymer hydrogen bonding and a 
strengthening of hydrophobic polymer-polymer interactions [84].  LCST drug carriers 
have been developed that expel encapsulated therapeutics upon heating above 
transition temperatures at therapeutically relevant temperatures by what is known as a 
“squeezing out” method upon collapse of the polymer system [4].  
While most biodegradable or self-assembled nanoparticle systems are formed 
from previously synthesized polymers, hydrogel nanoparticles are most commonly 
synthesized using heterogeneous polymerization techniques.  Because the hydrogel 
nanoparticles are formed during polymerization, incorporating a therapeutic at this 
stage requires exposing the drug to polymerization conditions that could potentially 
damage or modify the drug.  However, the porous characteristics of nanogel matrices 
allows for drug loading following polymerization by partitioning methods, which 
eliminates the need to subject the drug to harsh polymerization conditions.  In most 
situations, the drug is loaded into the nanogel by incubating the nanoparticles with the 
drug in aqueous conditions such that the particles are in their most swollen state.  After 
a period of time to allow the therapeutic to diffuse into the polymer matrix, a condition 
(most commonly pH or temperature) is altered, leading to a particle size transition to a 
more collapsed state with a smaller mesh size, physically entrapping the therapeutic in 
the polymer matrix. 
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Hydrogel nanoparticles, or nanogels have been synthesized using several 
techniques including dispersion and emulsion polymerization as well as step and flash 
imprint lithography [78, 85, 86].  These nano-scale hydrogels show rapid response rates, 
swelling quickly with small changes in stimuli.  Synthetic nanogels have stimuli-sensitive 
properties similar to their bulk hydrogel counterparts, exhibiting volume phase 
transitions in response to pH, temperature, electric field, or other environmental stimuli 
[87]. 
Several heterogeneous polymerization techniques have been used to synthesize 
monomers directly into the desired polymer hydrogel nanoparticles.   Two commonly 
used techniques are emulsion and dispersion polymerizations, and both are used to 
synthesize the various temperature-sensitive polymers in the proposed therapeutic 
systems.  Oil-in-water emulsions are commonly used to synthesize hydrophobic 
polymers from similarly hydrophobic monomers. Polymerization occurs in micelles that 
are formed with the addition of surfactant as monomers diffuse from large droplets into 
micelles and react with initiator [88].  Similarly, water-in-oil emulsions have been used 
to synthesize polymers from more water soluble molecules.  Previous work in this group 
featured the use of consecutive water-in-oil microemulsion polymerizations to 
synthesize IPN nanoparticles, and this technique has been adapted for use in this thesis.  
Monomer and crosslinker are dissolved in an aqueous phase and emulsified into a 
cyclohexane oil phase with surfactant.  Initiator is added to start the polymerization in 
the aqueous micelles [89]. 
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Dispersion polymerization has been used in free radical polymerizations where 
the growing polymer is much less soluble in a particular solvent than the monomer.  
Monomer and initiator are dissolved in a solvent in a homogenous mixture often with 
the inclusion of some molecule to act as a steric stabilizer for particle formation.  As 
polymerization begins, growing macroradicals precipitate, and form stabilized particles. 
Continued polymerization occurs as the particles are slightly swollen in the 
polymerization medium [90].  An aqueous dispersion polymerization has been used to 
synthesize temperature-sensitive hydrogel polymers with LCST behavior.  Nanoparticles 
of PNIPAAm and related copolymers have been synthesized by reaction of monomers in 
aqueous medium at elevated temperature with or without steric stabilizer molecules 
such as sodium dodecyl sulfate (SDS) [91].  The reaction is performed at a temperature 
well above the LCST of the resultant polymer.  Since the temperature is above the LCST, 
the polymer is immiscible in the aqueous environment and particle nucleation occurs. 
The hydrophilic nature of hydrogel systems makes them an ideal candidate for 
the loading and delivery of water soluble therapeutics such as protein or nucleic acid 
biomacromolecules.  Several nanogel systems have been investigated for the delivery of 
insulin to the small intestine.  In addition to their ability to entrap the water soluble 
insulin, some of these systems have advantageous pH-sensitive properties allowing 
them to protect insulin in the acidic environment of the stomach and release it in the 
more neutral pH of the small intestine [92, 93].   
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Polybasic nanoparticles consisting of cationic pH responsive hydrogels with PEG 
grafts, have been synthesized by a UV-initiated free radical emulsion polymerization was 
used to synthesize poly[2-(diethylamino) ethyl methacrylate] surface grafted with PEG 
(PDGP) nanogels.  Insulin as a model drug was added to a solution of these nanogels and 
the pH was adjusted to 6.5 to swell the nanoparticles.  After a loading period the pH was 
raised quickly to 7.4 to collapse the particles and entrap the loaded protein.  The loaded 
nanogels were dialyzed against water for 5 days to remove any excess protein not 
loaded.  Encapsulation efficiencies were measured up to 92% for insulin in PDGP 
particles with low crosslinking densities when equal weights of particles and protein 
were added to the loading solution [94].   
Controlled drug loading and release has also been shown in several studies using 
hydrogels based on the temperature-sensitive polymer poly(N-isopropylacrylamide) 
(PNIPAAm).  PNIPAAm exhibits a negative swelling transition at 34 °C, which makes it an 
attractive system from a physiological standpoint for applications in drug delivery.  For 
example, poly(NIPAAm) and poly(NIPAAm-co-AA) nanoparticles were loaded with 5-
fluorouracil and release was shown to be a function of pH and temperature [95].   
Nanogels of poly(vinyl alcohol), PVA, and poly(vinyl pyrrolidone), PVP have also 
been investigated for drug delivery applications.  For example, composite systems of 
PVA-crosslinked PVP nanogels were used to entrap ferromagnetic particles as well as 
bleomycin A5 hydrochloride.  Nanogels were prepared using a water-in-oil emulsion 
polymerization initiated by gamma ray irradiation.  For this emulsion polymerization, 
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the aqueous phase contained the PVA, PVP, and the ferromagnetic particles.  The 
resulting nanogels entrapped the ferromagnetic particles and were then used to load 
bleomycin A5 hydrochloride.  Dry nanoparticles were allowed to swell in an aqueous 
solution containing the drug, sonicated, and then placed on a shaker plate for 12 h of 
storage until no apparent liquid was visible.  Encapsulation efficiency was not reported, 
because it was assumed that all of the drug had been immobilized, but in vitro release 
occurred over a minimum period of 8 hours [96]. 
While most hydrogel nanodelivery systems have been used to entrap hydrophilic 
molecules, recent work on modified hydrogels has demonstrated the potential to load 
hydrophobic drugs as well.  In order to do so, the hydrophobicity of the nanogels has 
been increased through the incorporation of amphiphiles into the hydrogel matrix.  An 
acrylated PEG-PPG-PEG triblock copolymer with both hydrophobic and hydrophilic 
groups was used to synthesize crosslinked nanoparticles via an inverse microemulsion 
using a PEG crosslinker.  Properties of the emulsion could be altered to control for 
particle sizes ranging from 50 to 500 nm.  These nanogels were then loaded with 
doxorubicin to determine their ability to carry hydrophobic drugs.  Doxorubicin, 
solubilized in chloroform with triethylamine, was added to an aqueous solution of 
nanoparticles and the chloroform was allowed to evaporate overnight. The results 
indicated that the formation of nanogels from amphiphilic macromers was a successful 
strategy for loading hydrophobic drugs in a hydrogel with up to 9.8% loading capacity of 
doxorubicin [97]. 
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2.5 GOLD NANOPARTICLES 
Metal nanoparticles are of interest for biomedical applications because of their 
optical properties, specifically the scattering and absorption of light over a wide range of 
wavelengths.  Gold and silver nanoparticles in particular have been used to absorb light 
in regions spanning the visible and near-infrared (NIR) [98].  These characteristics have 
been investigated for applications in medical imaging, drug delivery, and biosensing [99-
101].  Metal particles capable of absorbing light in the NIR region are of interest for the 
applications discussed in this thesis, because light in this region is physiologically 
transmissive and not harmful to tissue [102].  Gold or silver nanoshells and gold 
nanorods have been demonstrated to absorb high amounts of light in this region and 
have been widely investigated for in vivo applications. 
Nanoshells consist of a thin metal shell around a dielectric core.  Commonly the 
core is silica and the surrounding metal shell is gold.  These gold nanoshells can be 
tuned to have peak absorbance at wavelengths of light ranging from 700-1100 nm.  By 
changing the ratio of the thickness of the gold shell to the diameter of the silica core the 
optical resonance varies from across wavelenths of the visible and NIR regions [103].  
For example, a gold nanoshell with a 60 nm diameter silica core and a 20 nm thick gold 
shell has a maximum optical resonance near 725 nm while the same silica core with a 
5nm gold shell displays peak resonance around 1025 nm [104].  By carefully controlling 
the size of the silica core and the growth of gold shell, particles can be formed with peak 
extinction in the NIR region where tissue transmissivity is highest.  Figure 2.1 shows a 
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TEM micrograph of gold nanoshells of roughly 80 nm in total diameter that exhibit peak 
extinction around 800 nm in the desirable NIR region. 
Many metal nanoparticles, particularly silver and gold, display strong absorption 
in the visible spectrum, typically ranging from yellow to reddish-brown [105].  By 
altering the size and in particular the shape of these nanoscale particles, absorption can 
be observed in nearly any part of the visible spectrum and into the infrared spectrum.  
Synthesis of structures ranging from nanospheres and nanowires to nanoprisms and 
nanoplates are reported in the literature exhibiting a variety of different visual 
appearances and absorbance spectra [106]. Gold nanorods are nanoscale spherocapped 
cylindrical particles. The nanorods show varying absorption spectra determined by the 
aspect ratio of the rods, which can be described using Mie theory.  Small changes in 
aspect ratio have dramatic effects on the optical properties of the particles, for example 
changing the aspect ratio of a gold nanorod over a range of approximately 3:1 to 7:1 
causes a red-shift from maximum absorption at 750 nm to 980nm [107].  Nanorods with 
aspect ratios near 4:1 such as those with a length of 40 nm and a width of 10 nm as 
shown in Figure 2.2 absorb strongly in the NIR region.  
An effect known as localized surface Plasmon resonance occurs when two 
metallic nanoparticles are in close proximity to each other, typically within about 2.5 
times the diameter of one of the particles [108].  When the particles are exposed to light 
there is a collective oscillation of electrons.  The extinction behavior becomes a function 
of not only the size and shape of the nanoparticle but also the distance between 
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adjacent particles and their orientation to each other.  For example, as 50 nm gold 
nanorods are moved closer together at distances less than 100 nm, the extinction 
spectrum becomes more red-shifted and the peak broadens.  
2.6 EXTERNALLY-CONTROLLED DELIVERY 
Externally-controlled or externally-triggered delivery systems are those in which 
some source external to the body can be used to create a signal to induce release a 
therapeutic at a desired time and location.  The external source in most cases is a form 
of electromagnetic radiation or an acoustic signal.  The signal must be able to penetrate 
through tissue to reach the delivery system.  Typically the signal will either induce 
heating in the delivery vehicle or interact mechanically with the system to trigger 
release.  These remotely controlled systems can have the same benefits as targeted 
systems in that they can improve therapeutic index locally while reducing systemic 
effects.  In some cases, externally controlled systems have been functionalized with 
targeting ligands to further improve efficacy.  
Externally applied electric fields, ultrasound, and mechanical forces have also 
been used to trigger a swelling transition and subsequent drug release [2, 5, 109]. For 
example ultrasound microbubbles have been developed for use as externally triggered 
delivery and imaging systems [110].  A focused ultrasound pulse can be used to disrupt 
the microbubbles and locally deliver a drug or contrast agent. 
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The swelling characteristics of temperature responsive hydrogels can be 
combined with a means to heat them via an external signal to trigger drug delivery.  
Heating can be triggered by several types of signals including light and magnetic fields.  
A magnetic field has been used to induce heating in a PNIPAAm hydrogel film system 
loaded with superparamagnetic iron oxide particles which triggers a negative swelling 
and release of a model drug [5].   
Other systems have been developed to control the release of a therapeteutic 
using light.  In one case, gold nanoshells have been incorporated into poly(N-
isoproplyacrylamide-co-acrylamide), P(NIPAAm-co-AAm), films or disks.  Upon exposure 
to certain wavelengths of light, gold nanoshells heat the polymer and trigger a negative 
swelling transition.  This behavior has been used to externally control the opening and 
closing of a microvalve and to trigger pulsatile release of insulin from a polymer loaded 
film [82, 111].   
Previous work in this laboratory has focused on developing a nanoscale system 
that incorporates light as the trigger to produce a temperature change, swelling 
transition, and subsequent drug release from UCST nanogel particles.  In the IPN 
systems that have been developed, complexation of the two networks occurs at low 
temperatures because of hydrogen bonding.  As the polymer is heated, hydrogen 
bonding begins to break down and a positive swelling transition is observed around 38-
42 °C [89].  A synthetic procedure has been developed for temperature-sensitive IPNs 
composed of interpenetrating networks of poly(acrylic acid), PAA, and poly(acrylamide), 
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PAAm [112].  The inverse-microemulsion produces particles between 100 nm and 1 μm 
in diameter, and there is potential to incorporate gold particles in the polymer matrix 
when added to the aqueous phase of the water-in-oil emulsion leading to a light-
triggered release system. 
2.7 PHOTOACOUSTIC IMAGING 
A contrast agent that absorbs nanopulsed light undergoes thermoelastic 
expansion in response to the pulsed laser light.  A temperature rise associated with the 
excitation from the nanopulsed light leads to thermal expansion.  This pulsed expansion 
produces ultrasonic waves that are detected by the transducer.  The detected acoustic 
signal can be used to reconstruct an image of the area of interest.  A number of 
materials have been used as contrast agents for photoacoustic imaging. 
Single-walled carbon nanotubes have been used as a contrast agent to image 
tumors [113].  The targeted carbon nanotubes were administered intravenously to mice 
with tumors and a photoacoustic signal was observed at the tumor that was 8 times 
stronger than the signal from nontargeted carbon nanotubes.   
Metal nanoparticles have been used as a contrast agent to induce an acoustic 
signal.  Gold nanoparticles, nanoshells, nanocages, and nanorods have all been used as 
contrast agents to create a photoacoustic signal when irradiated with short pulses of 
light [114-118].  Silver nanosystems have also been used as a contrast agent for 
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photoacoustic imaging [119].  In another system gold coated ferromagnetic cobalt 
nanoparticles were shown to be an effective contrast agent [120]. 
2.8 CONCLUSIONS 
Because of the adverse health effects associated with systemic delivery of 
therapeutic agents such as anticancer drugs there is great interest in developing 
systems that can deliver a therapeutic locally to a disease site.  In the case of 
chemotherapy, the use of nanoscale drug delivery systems is of interest because of their 
ability to passively target tumors, and in some cases actively target following  
functionalization of these particulate systems with targeting ligands.  Externally-
triggered systems can go one step further by precisely controlling the time and place 
that a drug is released.  There is a great need for improved systems that can better 




























Figure 2.1 TEM micrograph of gold nanoshells formed from a gold shell on a silica core 




Figure 1.2 TEM micrograph of gold nanorods having 4:1 aspect ratio leading to peak 
absorption at 808 nm. 
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 Chapter 3:  OBJECTIVES  
Delivery systems that can more carefully direct a therapeutic to a site of interest 
have several advantages over systemic delivery of a therapeutic.  Targeted delivery 
systems can be used to localize the release of a drug or other therapeutic compound at 
a disease site while minimizing or eliminating distribution of the drug to other parts of 
the body.  The development of externally-controlled therapeutic systems seeks to take 
this type of therapy a step further by precisely controlling when and where a 
therapeutic is delivered.   
The overall goal of this research was to develop systems that are capable of 
carrying a therapeutic and releasing it in response to a near-infrared (NIR) light trigger.  
Because NIR light penetrates safely through tissue, a disease site of interest such as a 
cancerous tumor could be exposed to the light causing nanoparticle carriers to release a 
drug at that location.   
The light-triggered drug delivery systems are composed of metal-polymer 
composites.  The nano-scale composites consist of gold nanorods covalently attached to 
or entrapped in a polymer network.  The gold nanorods are capable of absorbing NIR 
light and converting it to heat which is transmitted to temperature responsive polymer 
nanoparticles.  The polymer nanoparticles undergo a size transition upon heating which 
could be used to trigger the release of the entrapped therapeutic.  The specific aims of 
this research are listed here: 
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(1) Synthesis, optimization, and characterization of equilibrium swelling 
behavior of temperature responsive hydrogel nanoparticles. 
(2) Formulation and characterization of gold-polymer composites using gold 
nanorods and temperature responsive hydrogel nanoparticles 
(3) Evaluation of the ability of the nanoparticle systems to entrap and release a 
model therapeutic 
(4) Investigation of the cytocompatibility of composite nanoparticle systems. 
(5) Investigation of the light-triggered properties of the system and the potential 
use as a contrast agent in medical imaging techniques. 
 
Each of these specific aims will be addressed in the chapters that follow.  
Polymer nanoparticle development described in Specific Aim #1 was discussed in 
Chapter 4.  Gold-polymer composite formulation indicated in Specific Aim #2 was 
covered in Chapter 5.  Specific Aim #2 and the investigation of loading and release 
properties will be detailed in Chapter 6.  Chapter 7 will cover all of the studies that 
indicate the potential use of these therapeutic systems in vivo as describe in Specific 
Aims #4 and 5.  Chapter 8 will conclude the discussions of the specific aims with an 
overview of the results from this work. 
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Chapter 4:  Polymer Nanogel Synthesis and Characterization  
4.1 INTRODUCTION 
Current standards of practice for chemotherapy are to administer drugs either 
orally or intravenously depending on the combination of therapeutics that is being 
administered.  Because these types of molecules generally work by interfering with 
growth or killing fast dividing cells, they can have significant adverse effects systemically 
on healthy cells in addition to the targeted disease cells.  Common chemotherapeutics 
that are used for breast cancer have a variety of potential adverse side effects.  Systemic 
chemotherapy is used for cancer treatment because of its benefits in overall reduction 
of tumor size, potential elimination of cancer cells that can not be surgically removed, 
and reduction of recurrence rates.  Because of the severity of many of the adverse 
effects associated with this important type of therapy, there is significant interest in 
developing more efficient delivery systems for chemotherapeutics.  
In order for a chemotherapeutic delivery system to be an improvement over 
traditional systemic delivery, it must be able to deliver a drug preferentially to cancer 
cells over healthy tissue.  Ideally, such a system would carry its entire therapeutic 
payload to the disease site and release it in such a location that the drug (or particle and 
drug) would only be uptaken by the cancer cells.  In this case a chemotherapeutic drug 
can be delivered at its maximum therapeutic concentration at the disease site that may 
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otherwise reach systemic toxicity levels leading to serious adverse effects if the same 
dose was administered systemically. 
Several strategies have been pursued to develop chemotherapeutic delivery 
systems.  In order to more efficiently localize delivery at a cancerous disease site, most 
modified chemotherapies that are currently available enhance delivery by taking 
advantage of the enhanced permeability and retention (EPR) effect.  Because of the fast 
growth of tumors, the vasculature tends to be leaky and lymphatic drainage poor.  Large 
molecular weight materials such as polymers or nanoparticles are preferentially 
extravasated and concentrated at tumor cites while small molecular weight drugs are 
retained at significantly lower concentrations [1-3].   
In order to increase the molecular weight of chemotherapeutic drugs and take 
advantage of the EPR effect, chemotherapeutic prodrugs have been formulated by 
conjugating a therapeutic to a polymer or other high molecular weight compounds such 
as proteins or lipids. Several polymer drug complexes have been synthesized using 
important chemotherapeutics including paclitaxel and doxorubicin and have shown 
positive results in clinical trials [4].  These polymer drug complexes have additional 
benefits in cancer treatment because they can increase the solubility of hydrophobic 
chemotherapy molecules, and the polymer-drug linker can be made to degrade in 
response to enzymes present at the cancer site. 
Because paclitaxel is poorly soluble in aqueous media it must be administered in 
a mixture of polyethoxylated castor oil (Cremophor) and ethanol and a typical 
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administration period takes at minimum 3 hours.  These solvents are known to 
contribute to toxicity of the treatments [5].    Alternative methods have been used to 
improve the solubility of the drug through conjugation.  Paclitaxel conjugated to poly(l-
glutamic acid) is highly soluble in water and has shown improved anti-tumor results in in 
vitro and animal models [6].  In Phase I and II clinical trials, results were positive, and 
measured adverse effects were greatly reduced compared to traditional paclitaxel 
administration.   
Additionally, delivery vehicles such as polymer nanoparticles, micelles, and 
liposomes have been developed to take advantage of the EPR effect and deliver a 
chemotherapeutic to a delivery site [2].  Particles smaller than 400 nm have been shown 
to extravasate leaky tumor vasculature via the EPR effect, and those smaller than 200 
nm may be even more effective [7].   The Doxil © system made by Johnson and Johnson 
is a pegylated liposome formulation of doxorubicin which has been approved for clinical 
use in the United States, and Myocet is another liposomal formulation that has been 
approved for use in Europe and Canada for treatment of breast cancer [8].  A 
nanoparticle composed of the protein albumin has been used to encapsulate paclitaxel 
and has been approved by the FDA for treatment of metastatic breast cancer [9]. 
Nanoparticle systems that incorporate externally-controlled behavior have the 
potential to go a step beyond the benefits of standard nanoparticle based treatments 
for breast cancer.  As the nanoparticles accumulate at the tumor site due to the EPR 
effect, they can be triggered to release the entire drug payload at the target site using 
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an external trigger such as a magnetic field, light, or radio frequency pulse.  Externally 
applied electric fields, ultrasound, and mechanical forces have also been used to trigger 
a swelling transition and subsequent drug release [10, 11]. In other work, so called 
ultrasound microbubbles have been developed for use as externally triggered delivery 
and imaging systems [12, 13].  A focused ultrasound pulse can be used to disrupt the 
microbubbles and locally deliver a drug or contrast agent. 
Past work in this group has focused on using stimuli-responsive hydrogel 
materials for a number of applications in biomaterials and drug delivery.  This thesis 
work seeks to combine absorption properties of metal nanoparticles with temperature 
responsive hydrogels to create systems that are capable of undergoing volume changes 
in response to light exposure.  Certain types of metal nanoparticles including gold or 
silver nanoshells and gold nanorods can be tuned to absorb light in the near-infrared 
(NIR) region which is of interest for biomedical applications because of the ability of 
light in this region to penetrate through tissue [14-18].   
Metal nanoparticles can convert absorbed light to heat when coupled to an 
adjacent stimuli-responsive hydrogel. Heat transmitted from the metal triggers a 
swelling response and an associated release of an entrapped therapeutic.   
Gold nanoshells have been entrapped in temperature responsive P(NIPAAm-co-
AAm) hydrogel films [11, 19].  These films have been shown to deswell upon exposure 
to NIR light, and when loaded with insulin, a light trigger can be used to induce a 
pulsatile release of insulin from the gels.  Using a similar concept, a magnetic field has 
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been used to induce heating in a PNIPAAm hydrogel film system loaded with 
superparamagnetic iron oxide particles which triggers a deswelling and release of a 
model drug [11].    
Two classes of temperature responsive polymer hydrogel nanoparticles have 
been synthesized and investigated in this thesis to produce systems that will have the 
positive effects associated with nanoparticle delivery while serving as the stimuli-
responsive basis for externally-triggered delivery systems.   Crosslinked polymers that 
exhibit lower critical solution temperature (LCST) behavior are more swollen at lower 
temperatures, and deswell or shrink upon heating through a transition temperature 
region.  The class of materials that have upper critical solution temperature (UCST) 
behavior behave in an opposite manner where they are in a more collapsed state at 
lower temperatures and swell above the transition temperature.  In either case, LCST or 
UCST, the temperature-responsive behavior can be utilized to trigger the release of a 
drug from the hydrogel carriers [20].   
Polymers demonstrating LCST behavior, most commonly poly(N-
isopropylacrylamide), PNIPAAm, and related copolymers, have been investigated for use 
as temperature sensitive drug carriers.  The presence of separate hydrophilic and 
hydrophobic groups in the polymer chain leads to this behavior.  At low temperatures, 
hydrogen bonding interactions between water and the hydrophilic groups lead to a 
swollen state, but an increase in temperature beyond the transition temperature leads 
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to weakening of the water-polymer hydrogen bonding and a strengthening of 
hydrophobic polymer-polymer interactions [21].   
To trigger release of an entrapped therapeutic, a polymer is designed so that in 
its swollen state the properties are such that the polymer can encapsulate and protect a 
molecule of interest in its swollen state. Upon deswelling or shrinking, there is a fast 
release as some of the encapsulated material is squeezed out of the polymer matrix [11, 
19].  As this cycle is repeated, a pulsatile release of the therapeutic may be observed. 
LCST carriers have been developed that expel encapsulated therapeutics upon heating 
above transition temperatures at therapeutically relevant temperature, by what is 
known as a deswelling method upon collapse of the system.  
Dispersion polymerization has been used in free radical polymerizations where 
the growing polymer is much less soluble in a particular solvent than the monomer.  
These methods can be applied to synthesis of certain LCST polymer nanoparticles.  
Monomer and initiator are dissolved in a solvent in a homogenous mixture often with 
the inclusion of some molecule to act as a steric stabilizer for particle formation.  As 
polymerization begins, growing macroradicals precipitate, and form stabilized particles. 
Continued polymerization occurs as the particles are slightly swollen in the 
polymerization medium [22].  An aqueous dispersion polymerization has been used to 
synthesize temperature-sensitive hydrogel polymers with LCST behavior.  PNIPAAm 
based nanoparticle systems have been synthesized using aqueous dispersion 
polymerizations and can be formulated using a stabilizing molecule such as sodium 
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dodecyl sulfate (SDS) or no surfactant at all [21, 23].  The reaction is performed at a 
temperature well above the LCST of the resultant polymer.  Since the temperature is 
above the LCST, the polymer is immiscible in the aqueous environment and particle 
nucleation occurs. 
Hydrogels with UCST behavior have characteristics such that at lower 
temperatures some polymer-polymer interactions lead to a less swollen state.  Upon 
heating through the UCST, these interactions are weakened so that the polymer 
effectively becomes miscible with the aqueous phase, but because the polymer is 
crosslinked the systems imbibes water and swells.  Certain types of interpenetrating 
polymer networks, IPNs, such as those based on acrylamide (AAm) and acrylic acid (AA) 
demonstrate this type of behavior with transition temperatures near 40 °C  [24].  IPNs 
consist of two separately crosslinked polymer networks that are physically entangled 
with the first network, but not covalently attached.  The PAA network and the PAAm 
network undergo hydrogen bonding at low temperatures, which breaks down above the 
UCST and electrostatic and steric interactions cause the polymer to swell.  If a 
therapeutic molecule is encapsulated in a carrier in its collapsed state where the drug is 
protected and small mesh size limits diffusion in or out of the polymer matrix [25].  If 
the polymer encounters an environment that triggers swelling, the mesh size increases, 
and there is an increase in the rate of diffusion so that the therapeutic is released into 
the surrounding environment.   
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In PAA/PAAm based IPN systems hydrogen bonding begins to break down and a 
positive swelling transition is observed around 38-42 °C [24].  A synthetic procedure has 
been developed for temperature-sensitive IPNs composed of interpenetrating networks 
of poly(acrylic acid), PAA, and poly(acrylamide), PAAm [26].  The inverse-microemulsion 
produces particles between 100 nm and 1 micron in diameter.  This method involves 
two consecutive water-in-oil microemulsion polymerizations.  The acrylamide monomer 
and crosslinker are dissolved in an aqueous phase and emulsified into a cyclohexane oil 
phase with surfactant.  Initiator is then added to start polymerization in the aqueous 
micelles and synthesize polyacrylamide microparticles or nanoparticles [26].   Following 
termination of the first reaction acrylic acid and crosslinker are added in a second 
aqueous phase and initiated to synthesize the PAA interpenetrating network that is not 
covalently attached to the PAAm network.    
4.2 MATERIALS AND METHODS 
4.2.1 LCST Nanoparticle Synthesis 
Acrylic acid (AA, inhibited with 200 ppm hydroquinone monomethyl ether), N-
Isopropylacrylamide (NIPAAm), and sodium dodecyl sulfate (SDS) were obtained from 
Sigma Aldrich (Milwaukee, WI), acrylamide (AAm) and ammonium persulfate (APS) were 
obtained from Fisher Scientific (Hampton, NH).  Acrylic acid was purified using vacuum 
distillation.  All other materials were used as received. 
 65 
Nanogels demonstrating LCST behavior were synthesized using an aqueous free 
radical dispersion polymerization.  Polymers were synthesized with various monomer 
feed ratios. Crosslinked PNIPAAM nanoparticles were synthesized along with several 
copolymers. Copolymers were synthesized that incorporated hydrophilic comonomers, 
either AAm or AA.  The AAm or AA were be added in molar ratios up to 10 % of total 
monomer.  Crosslinking molar feed ratios were also varied from 1 to 10 %. 
To synthesize LCST polymers monomer, crosslinker, N,N’-Methylene 
bisacrylamide, and a stabilizer, sodium dodecyl sulfate (SDS) are added to a 100 ml 
aqueous phase in a 250 ml round bottomed flask at a total monomer concentration of 
5.5 g/L and a typical stabilizer concentration of 0.3 g/L.  Monomers are pictured in 
Figure 4.1.  The monomers and stabilizer were first dissolved in the aqueous medium.  
Next, the aqueous reaction solution was purged with nitrogen to remove oxygen from 
the reaction flask.  A 70 °C oil bath was prepared and the purged reaction flask was 
submerged in the oil bath.  An aqueous solution of the free radical initiator, APS, was 
injected into the reaction flask to initiate reaction.  The reaction was allowed to proceed 
for at least two hours.  After completion, the reaction flask was opened to the air and 
removed from the heat source. 
The resulting nanoparticle suspension was dialyzed against DI water for 10 days 
using a 12-14,000 MWCO dialysis tubing (Spectrum Laboratories, Rancho Domingo, CA) .  
Dialysis water was changed twice daily.  Particle solutions were then frozen in a -80° C 
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freezer and lyophilized until dry.  Dry particle solutions were resuspended in the 
appropriate medium or used dry as necessary for further analysis. 
4.2.2 UCST Nanoparticle Synthesis 
Acrylic acid (AA, inhibited with 200 ppm hydroquinone monomethyl ether), N,N’-
methylenebisacrylamide (MBAAm), polyethylene glycol laurylether (Brij 30), 
cyclohexane, and sodium bis(2-ethylhexyl) sulfosuccinate (AOT) were obtained from 
Sigma Aldrich (Milwaukee, WI),  acrylamide (AAm) and lauroyl peroxide were obtained 
from Fisher Scientific (Hampton, NH).  Acrylic acid was purified using vacuum distillation.  
All other materials were used as received. 
Procedures developed previously within the lab were used to synthesize 
temperature-responsive nanogels exhibiting UCST behavior [26].  The particles 
composed of acrylamide (AAm) and acrylic acid (AA) were synthesized using a two-step 
inverse (water-in-oil) microemulsion free radical polymerization.  The inverse emulsion 
solution consisted of a cyclohexane continuous phase, surfactants, and an aqueous 
phase split into two separate mixtures one for each of the two reactions, containing 
monomer, initiator, and water. The only difference in these two aqueous solutions was 
that one contains only AAm monomer and the other only AA monomer. 
A typical polymerization medium consisted of 81% cyclohexane oil phase, 13% 
surfactants, and 6% total aqueous phase by weight.  The surfactant mixture was a 50:50 
weight percent mixture of Brij 30 and AOT.  The aqueous phase typically consisted of 
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approximately 80% water and 5% initiator by weight with the remaining balance 
consisting of monomer and crosslinker, N,N’-Methylene bisacrylamide (MBAAm), in the 
desired synthesis ratio. Figure 4.2 displays the monomers used in the polymerization.   
The surfactant was dissolved first in cyclohexane.  AAm monomer along with 
MBAAm crosslinker was dissolved in the separate water phase.  The first premixed 
aqueous phase containing AAm monomer was added to the cyclohexane and the 
mixture of the two phases along with surfactant was homogenized at 24,000 RPM for 5 
minutes.  The reaction flask was then purged with nitrogen for 30 minutes to remove 
oxygen from the system which acts as a free radical scavenger. 
An oil bath was prepared at 60 °C .  The reaction was initiated following the 
purge by immersion in the oil bath to heat to 60 °C.  After reaction for 2 hours, the 
reaction was terminated by removal from the heat source and exposure to the 
atmosphere.  The second aqueous monomer phase was then prepared. The second 
aqueous phase, consisting of AA and additional initiator and crosslinker, is added to the 
reaction flask and again homogenized, purged, and reacted for 2 hours at 60 °C to form 
a second crosslinked polymer network that is physically entangled with the first 
network, but not covalently attached. 
After synthesis the cyclohexane solvent was removed using rotary evaporation 
under vacuum at 40 °C.  Five successive ethanol wash cycles were used to wash the 
polymer.  One wash cycle consisted of suspension of approximately 0.5 g of 
nanoparticles in 25 ml of ethanol and centrifugation at 3200 rcf.  Ethanol supernatant 
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was then removed and particles resuspended in ethanol for the next wash.  After 
ethanol washing the particles were suspended in DI water and dialyzed for 10 days using 
a 12-14,000 MWCO dialysis tubing with dialysis water being changed twice daily.  
Particle solutions were then frozen in a -80° C freezer and lyophilized until dry.  Dry 
particle solutions were resuspended in the appropriate medium or used dry as 
necessary for further analyses. 
4.2.3 Nanoparticle Swelling Characterization by Dynamic Light Scattering 
Dynamic light scattering was used to quantify the swelling behavior of nanogels 
in response to pH or temperature.  The hydrodynamic diameter of the particles in 
solution was determined using a dynamic light scattering (DLS, ZetaPlus, Brookhaven, 
Holtsville, NY) instrument operating at a 90˚ scattering angle with a 635 nm 35 mW 
diode laser source.   
Freeze-dried LCST nanoparticle samples were resuspended in PBS buffer for 
temperature responsive swelling measurements at a pH of 7.4.  The concentration of 
the particle solution was adjusted as necessary to achieve a photon count rate of 
approximately 300,000 counts per second.  Hydrodynamic diameter was measured over 
a temperature range from 10 °C to 50 °C in increments of 2 °C or 5 °C. 
The copolymers of NIPAAm and AAm were characterized for their temperature 
sensitive behavior at molar feed ratios ranging from 95/5 to 80/20 NIPAAM:AAm.  
Copolymers composed of NIPAAm and AA were synthesized and examined at similar 
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compositions.  Polymers with crosslinking ratios ranging from 1-10 % molar feed ratio 
were also characterized for their temperature sensitive swelling behavior. 
To measure the swelling behavior or PAAm/PAA IPN systems freeze-dried 
particles were suspended in a DMGA buffer solution and adjusted to a pH of 3.5 using 
NaOH.  Concentration of the particle solution was adjusted as necessary to achieve a 
photon count rate of 300,000 counts per second.  Hydrodynamic diameter was 
measured over a temperature range from 10 °C to 50 °C.   
4.2.4 Polymer Nanoparticle Characterization  
Electron microscopy was performed to analyze particle size, morphology, and 
polydispersity.  Both transmission electron microscopy (TEM) and scanning electron 
microscopy (SEM) techniques were used.  
Freeze-dried particles were imaged with a LEO 1530 scanning electron 
microscopy (Carl Zeiss AG; Oberkochen, Germany). Microgels were placed onto double 
sided conductive tape attached to an aluminum SEM stage (Ted Pella, Inc.; Redding, CA) 
and sputter coated with gold. 
TEM samples were prepared by placing 5 µl of aqueous particle suspension on a 
formvar coated copper TEM grid (Electron Microscopy Sciences, Hatfield, PA).  After one 
minute, the grid was blotted dry using filter paper.  Particles were imaged using a FEI 
Tecnai Transmission Electron Microscope (FEI; Hillsboro, OR) operating at 80 kV 
equipped with a top mount AMT Advantage HR 1kX1k digital camera. 
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4.3 RESULTS AND DISCUSSION 
4.3.1 LCST Nanoparticle Synthesis 
Several types of LCST nanoparticle systems were synthesized by varying 
parameters of the polymerization to find optimized systems.  These nanocarrier systems 
must be able to entrap a drug in a swollen state and limit diffusion of the drug out of the 
system, have a swelling transition around 40 °C, and quickly deswell upon heating to 
release a drug.  They also should have a size of less than 300 nm in their most swollen 
state to take advantage of the EPR effect and to limit clearance by the 
reticuloendothelial system.  The amount of stabilizing molecule, SDS, in the solution was 
varied as well as the amount of crosslinker in the polymerization. 
Nanoparticles composed of 10% mol crosslinked PNIPAAm that were synthesized 
with varying amounts of SDS demonstrate that there is a relationship between the 
amount of SDS in the dispersion and the resulting size of the nanoparticles.  Figure 4.3 
shows that as the amount of SDS in the dispersion is decreased there is a decrease in 
average particle size as measured by dynamic light scattering in PBS.  
The copolymers P(NIPAAm-co-AAm) and P(NIPAAm-co-AA) were successfully 
synthesized as nanoparticles using the aqueous dispersion polymerization.  Synthesis of 
these copolymers at an SDS concentration of 0.3 g/L produced spherical nanoparticles 
with hydrodynamic diameters in the desired range.  
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Crosslinking ratio is an important parameter when considering a LCST hydrogel 
based drug delivery system.  The crosslinking ratio affects the mesh size of the polymer 
which must be small enough to entrap and protect the therapeutic at 37 °C, but such 
that there is release when the polymer shrinks and squeezes out the drug.  Dispersion 
polymerization was used to successfully synthesize LCST polymer nanoparticles with 
molar extents of crosslinking between 1 and 10%.  Crosslinking ratio also affects the size 
of the nanoparticle and swelling behavior which is discussed in detail in section 4.3.3.  
More highly crosslinked polymers have more tightly bound networks and a smaller 
relative mesh size which has important implications for therapeutic loading which are 
described in detail in Chapter 6.   
4.3.2 UCST Nanoparticle Synthesis 
IPN nanoparticle systems with UCST behavior were synthesized by varying 
parameters of the polymerization to find optimized systems.  These nanocarrier systems 
must be able to entrap a drug in the collapsed state and limit diffusion of the drug out of 
the system, have a swelling transition around 40 °C, and quickly swell upon heating 
above the transition temperature to release a drug.  They also should have a size of less 
than 300 nm in their most swollen state to take advantage of the EPR effect and to limit 
clearance by the RES.  Previous work demonstrated that the surfactant phase wt % 
could be increased to decrease particle size.  A surfactant weight ratio of 15% leads to 
particles below the 300 nm size threshold.  Figure 4.4 shows a typical size distribution of 
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50/50 PAAm/PAA IPN nanoparticles synthesized under these conditions.  Swelling 
behavior was characterized for the IPN systems using DLS at crosslinking molar feed 
ratios between 1 and 10% as shown in Figure 4.5. 
Crosslinking ratio is also an important parameter when considering a UCST 
hydrogel delivery system.  The crosslinking ratio affects the mesh size of the polymer 
which must be small enough to entrap and protect the therapeutic at 37 °C, but such 
that there is release due to diffusion when the polymer swells above the transition 
temperature.  Water-in-oil microemulsion polymerization was used to successfully 
synthesize IPN nanoparticles with molar extents of crosslinking of 1%, 5%, and 10%.  
Crosslinking ratio also affects the size of the nanoparticle and swelling behavior which is 
discussed in detail in Section 4.3.3.  As with LCST systems a more highly crosslinked 
network leads to a smaller mesh size which is necessary to entrap smaller molecular 
weight molecules. 
4.3.3 Polymer Nanoparticle Characterization by Dynamic Light Scattering 
In order for LCST hydrogel nanocarriers to be of use in externally-controlled drug 
delivery systems, they must have a negative swelling transition that occurs just above 
body temperature, approximately 40 °C.  Optimized systems should have the largest 
swelling differential possible between the 37 °C body temperature and a temperature of 
42 °C where healthy cell death may begin.  Addition of the more hydrophilic monomers 
AAm or AA led to an increase in the swelling transition temperature or LCST.  Several 
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synthesis parameters were examined to compose an optimized temperature-responsive 
nanoparticle system, including monomer feed composition and crosslinker feed ratio.   
Dynamic light scattering results that demonstrate swelling behavior have been used to 
determine the LCST swelling transition and volume swelling ratios of the various 
systems. 
Crosslinked homopolymers of PNIPAAm synthesized at different crosslinking 
ratios displayed unique swelling behavior.  As seen in Figure 4.6 as the molar fraction of 
crosslinking agent in the feed was increased there was an accompanying decrease in 
total volume swelling ratio observed when considering the maximum swelling volume 
compared to the minimum swelling volume.  Less crosslinker in the feed leads to a 
looser network structure that will swell to a larger size than the tight network structure 
that results from a feed with a higher ratio of crosslinker.  When the particles are in the 
most collapsed state it is clear that crosslinking ratio does not have a great effect on 
particle size.  Volume swelling ratio based plots are shown in Figure 4.7.  As the particles 
collapse to the point where the chains are so close together the amount of crosslinking 
does not play a significant role.   
The hydrophilic monomers AAm and AA were added along with NIPAAm to 
synthesize copolymer nanoparticles that will exhibit LCST behavior with higher LCST 
transition temperatures.  As shown in Figure 4.8 the addition of 10% molar ratio of 
either AAm or AA to the feed shifts the transition temperature higher than when 
compared to the homopolymer at 10% extent of crosslinker.   Similar swelling curves 
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based on volume swelling ratio are produced in Figure 4.9. Copolymers with a 90/10 
ratio have a temperature based swelling transition that takes place in a region which is 
of interest for the applications described in this thesis.  Particles can be loaded in their 
most swollen state at temperatures below physiological, will be slightly collapsed to 
entrap a drug at 37 °C, and will further decrease in size upon heating above this 
temperature. 
IPN nanoparticles demonstrating UCST behavior were synthesized with various 
crosslinking ratios.  As the percent of crosslinker in the feed is reduced the volume 
swelling ratio increases.  A high amount of crosslinker in the feed leads to a tightly 
bound network structure and an associated decrease in ability to swell as much as a 
more lightly crosslinked, loose structure.   
4.3.4 Polymer Nanoparticle Characterization by Electron Microscopy 
Scanning electron microscopy was used to confirm the spherical shape of 
nanoparticles and to examine morphology.  All PNIPAAm based materials displayed a 
spherical shape with a low polydispersity and smooth surfaces.  An SEM micrograph of 
representative PNIPAAm nanoparticles in Figure 4.10.    
Transmission electron microscopy was used as a means to further confirm the 
spherical nature of the nanoparticles.  TEM samples were prepared by depositing 
nanoparticles on a TEM grid directly from aqueous suspensions.  Microscopy images 
confirm the results from SEM of spherical nanoparticles and appear to be even less 
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polydisperse when they have not been dried by lyophilization as the SEM procedure 
required.  A TEM image of PNIPAAm particles is shown in Figure 4.11 and P(NIPAAm-co-
AA) in figure 4.12.   
UCST nanoparticles were also imaged using electron microscopy techniques. IPN 
nanoparticles are spherical with smooth morphologies and an SEM micrograph is shown 
in Figures 4.12.  IPN nanoparticles are shown in a representative TEM micrograph 
labeled as Figure 4.13. 
4.4 CONCLUSIONS 
Several types of temperature responsive nanogels were synthesized for use in 
drug delivery systems.  Particles exhibiting LCST behavior including PNIPAAm, 
P(NIPAAm-co-AAm), and P(NIPAAm-co-AA) were synthesized using an aqueous 
dispersion polymerization.  Copolymers with varying monomer ratios were examined for 
their ability to tune the LCST of the systems and the ability to increase the temperature 
of this transition by addition of a more hydrophilic monomer was confirmed. IPN 
nanoparticles exhibiting UCST behavior composed of equimolar networks of PAA and 
PAAm were formulated with a water in oil microemulsion polymerization.  The effect of 
surfactant concentration and crosslinking ratio on size and swelling behavior of the 
nanoparticles was analyzed.  Polymer size, shape, and morphology were verified using 
microscopy techniques including SEM and TEM.  The characterizations can be used to 
gain insight into the potential of these systems as nanoscale drug carriers, where the 
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determination of size and swelling behavior can be used to select the appropriate 
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Figure 4.1 Monomers used in the synthesis of polymer nanoparticles with UCST 
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Figure 4.2 Monomers used in the synthesis of polymer nanoparticles with LCST behavior 




Figure 4.3 Hydrodynamic diameters of PNIPAAm hydrogel particles with varying 


































































Figure 4.5 Equilibrium swelling behavior of IPN nanoparticles with varying molar extents 
of crosslinking based on intensity based hydrodynamic diameters from 





Figure 4.6 Equilibrium swelling behavior of PNIPAAm nanogels with varying molar 
extents of crosslinking based on intensity based hydrodynamic diameters 

































































Figure 4.7 Equilibrium volume swelling ratios of PNIPAAm nanogels with varying molar 
extents of crosslinking based on intensity based hydrodynamic diameters 











































Figure 4.8 Equilibrium swelling behavior of PNIPAAm, 90/10 P(NIPAAm-co-AAm), and 
90/10 P(NIPAAm-co-AA) nanogels with 10% molar extent of crosslinking 
based on intensity based hydrodynamic diameters from dynamic light 




































Figure 4.9 Equilibrium volume swelling ratios of PNIPAAm, 90/10 P(NIPAAm-co-AAm), 
and 90/10 P(NIPAAm-co-AA) nanogels with 10% molar extent of 
crosslinking based on intensity based hydrodynamic diameters from 
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Chapter 5: Gold-Polymer Composite Nanoparticle Synthesis and 
Characterization  
5.1 INTRODUCTION 
In order to develop the externally-controlled light-responsive nanoparticle 
systems, a component must be introduced into the system that will lead to the heating 
of the polymer layer which triggers the swelling response and associated drug release.  
The heating element must meet several criteria.  First, it must be on the nanoscale so 
that the entire particle systems are at most 400 nm in diameter.  Second, the 
component must be able to heat in response to exposure to light in the near infrared 
(NIR) region.  Light with wavelengths in the NIR region is of interest because there is a 
minimum in the absorption characteristics of the main absorbers is tissue in this region 
including water and hemoglobin.  Several types of metal based nanoparticles are of 
interest because they are capable of absorbing light in this region and converting it to 
heat. 
Nanoshells consist of a thin metal shell around a dielectric core.  Commonly the 
core is silica and the surrounding metal shell is gold.  These gold nanoshells can be 
tuned to have peak absorbance at wavelengths of light ranging from 700-1100 nm.  By 
changing the ratio of the thickness of the gold shell to the diameter of the silica core, 
the optical resonance varies from across parts of the visible and near infrared regions 
 95 
[1].  For example a nanoshell with a 60 nm diameter silica core and a 20 nm thick gold 
shell has a maximum optical resonance near 725 nm while the same silica core with a 5 
nm gold shell displays peak resonance around 1025 nm [2].  By carefully controlling the 
size of the silica core and the growth of gold shell, particles can be formed with peak 
extinction in the NIR region where tissue transmittance is highest.  Figure 5.1 shows a 
TEM micrograph of gold nanoshells of roughly 80 nm in total diameter that exhibit peak 
extinction around 800 nm in the desirable near-infrared region. 
Many metal nanoparticles, particularly silver and gold, display strong absorption 
in the visible spectrum, typically ranging from yellow to reddish-brown [3].  By altering 
the size and in particular the shape of these nanoscale particles, absorption can be 
observed in nearly any part of the visible spectrum and wavelengths into the infrared 
spectrum.  Synthesis of structures ranging from nanospheres and nanowires to 
nanoprisms and nanoplates are reported in the literature exhibiting a variety of 
different visual appearances and absorbance spectra [4].  
Gold nanorods are nanoscale spherically capped cylindrical particles. The 
nanorods show varying absorption spectra determined by the aspect ratio of the rods 
which can be described using Mie theory.  Small changes in aspect ratio have dramatic 
effects on the optical properties of the particles, for example changing the aspect ratio 
of a gold nanorod over a range of approximately 3:1 to 7:1 causes a red-shift from 
maximum absorption at 750 nm to 980 nm [5].  Nanorods with aspect ratios near 4:1 
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such as those with a length of 40 nm and a width of 10 nm as shown in Figure 5.2 absorb 
strongly in the NIR region. 
Gold nanorods were selected for use in the composite systems developed in this 
thesis.  The smaller size of the gold nanorods with peak absorption at 800 nm 
(approximately 40 nm in length) will allow them to be incorporated into composite 
systems that will have total diameters below 400 nm in their drug entrapping states.  
Nanoshells that have the required properties would be closer to 100 nm in diameter 
making composite delivery systems considerably more bulky.  Gold nanorods also have 
been shown to have higher absorption values and associated heating when compared to 
similar nanoshells. 
A composite nanoparticle system is of interest in order to couple the gold 
nanorod heating element to the temperature sensitive polymer hydrogel carrier.  Metal-
polymer composites have been formed for a variety of applications in past work.  Much 
of this work has focused on entrapping metal nanoparticles within larger polymer 
matrices.  Systems that incorporate both metal and polymers have been synthesized 
through direct polymerization, assembly of polymers around nanoscale metals, or 
attachment of metals to functional polymers [6]. 
Past work has been done in the development of temperature based externally 
controlled systems. In one case where light was used an external trigger, gold 
nanoshells have been incorporated into poly(N-isoproplyacrylamide-co-acrylamide), 
P(NIPAAm-co-AAm), films or disks.  Upon exposure to certain wavelengths of light, gold 
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nanoshells heat the polymer and trigger a negative swelling transition.  This behavior 
has been used to externally control the opening and closing of a microvalve and to 
trigger pulsatile release of insulin from a polymer loaded film [7, 8].  
In this thesis, gold nanorods have been grafted to polymer nanoparticles using a 
peptide bond so that they will heat the adjacent polymer hydrogel network.  A 
schematic of the particle system is shown in Figure 5.3.  The amide bond covalently 
attaching the nanorods to the particles is formed by coupling an amine and a carboxyl 
group.  Gold nanorods have been functionalized with a poly(ethylene glycol) (PEG) 
linking molecule with a primary amine group termination.  All of the temperature 
responsive polymer nanoparticles used for composite synthesis included acrylic acid in 
the polymerization so that there were free carboxyl groups on the surface of the 
hydrogel for grafting of the gold nanorods.  Carboxyl groups can be activated for this 
type of condensation reaction by the inclusion of one or more catalysts to act as leaving 
groups during the reaction.  Water soluble carboxyl activating agents, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and N-Hydroxysulfosuccinimide (sulfo-NHS) 
were used here to graft the gold nanorods to the surface of the polymer nanoparticles. 
The mechanism for the peptide coupling reaction using EDC is shown in Figure 5.4.   
An effect known as localized surface plasmon resonance occurs when two 
metallic nanoparticles are in close proximity to each other, typically within about 2.5 the 
diameter of one of the particles [9].  When the particles are exposed to light, there is a 
collective oscillation of electrons.  The extinction behavior becomes a function of not 
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only the size and shape of the nanoparticle but also the distance between adjacent 
particles and their orientation to each other.  For example, as 50 nm gold nanorods are 
moved closer together at distances less than 100 nm the extinction spectrum becomes 
more red-shifted and the peak broadens.  As the composite gold-polymer nanoparticles 
go towards the more collapsed structure and the gold nanoparticles are drawn closer 
together these plasmon coupling effects are likely to occur.  
5.2 MATERIALS AND METHODS 
5.2.1 LCST Composite Nanoparticle Synthesis 
Acrylic acid (AA, inhibited with 200 ppm hydroquinone monomethyl ether), N-
Isopropylacrylamide (NIPAAm), and sodium dodecyl sulfate (SDS) were obtained from 
Sigma Aldrich (Milwaukee, WI), acrylamide (AAm) and ammonium persulfate (APS) were 
obtained from Fisher Scientific (Hampton, NH). Bare gold nanorods and gold nanorods 
with Amine-terminated PEG chains, N-therapy amine-polymer gold nanorods, were 
obtained from Nanopartz (Loveland, CO).  Acrylic acid was purified using vacuum 
distillation.  All other materials were used as received. 
Composite systems incorporating temperature-sensitive polymers were 
synthesized using two different methods.  The first method involved dispersing gold 
nanorods in the pre-polymerization aqueous solution.  Polymerization proceeded using 
an aqueous dispersion polymerization method and gold nanorods served as nucleation 
points, entrapping them inside of polymer nanoparticles. 
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Crosslinked PNIPAAM composite nanoparticles were synthesized along with 
P(NIPAAm-co-AAm), and P(NIPAAm-co-AA) at molar crosslinking ratios of 10 %. To 
synthesize LCST composite monomer, crosslinker, N,N’-Methylene bisacrylamide, and a 
stabilizer (usually SDS) are added to a 100 ml aqueous phase in a 250 ml round 
bottomed flask at a total monomer concentration of 5.5 g/L and a typical stabilizer 
concentration of 0.3 g/L.  The monomers and stabilizer were first dissolved in the 
aqueous medium. 2 ml of gold nanorods were added to the polymerization flask at a 
concentration of approximately 0.2 mg/ml.  Next, the aqueous reaction solution was 
purged with nitrogen to remove oxygen from the reaction flask.  A 70 °C oil bath was 
prepared and the purged reaction flask was submerged in the oil bath.  An aqueous 
solution of the free radical initiator, APS, was injected into the reaction flask to initiate 
reaction.  The polymerization was allowed to proceed for at least two hours.  After 
completion, the reaction flask is opened to the air and removed from the heat source. 
The resulting composite nanoparticle suspension was dialyzed against DI water 
for 10 days using a 12-14,000 MWCO dialysis tubing.  Dialysis water was changed twice 
daily.  Particle solutions were then frozen in a -80° C freezer and lyophilized until dry.  
Dry particle solutions were resuspended in the appropriate medium or used dry as 
necessary for further analysis. 
Transmission Fourier transform infrared (FT-IR) spectrometry was performed on 
freeze dried nanogels dispersed in potassium bromide (KBr) to verify synthesis of 
P(NIPAAm-co-AA).  KBr was dehydrated at 125 °C prior to use to remove water. Samples 
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were mixed with KBr at 1-2wt% and crushed with a mortar and pestle.  Approximately 
200mg of this powder dispersion was pressed into clear, 13 mm pellets using a hydraulic 
press and evacuable potassium bromide die. IR spectra were recorded using a Nicolet 
Magna IR-560 FTIR Spectrophotometer. The machine was purged with nitrogen gas for 
at least two hours before acquiring spectra.  Each spectrum was an average of 100 scans 
with a resolution of 4 cm-1. 
The second method to synthesize PNIPAAm based gold-polymer systems 
consisted of grafting gold nanorods to the surface of the polymer nanoparticles.  First 
P(NIPAAm-co-AA) with 10 mol % crosslinking feed ratio were synthesized using aqueous 
dispersion polymerization as previously described.  Gold nanorods were received 
capped with a PEG chain with a primary amine on the terminal end of the PEG.  The 
attachment of the PEG chain to the gold nanorods is achieved by reacting a 
heterobifunctional PEG molecule with a thiol group on one end and the primary amine 
on the other with the gold.  
 A condensation reaction was used to form a peptide bond grafting the gold 
nanorods to the surface of the polymer nanoparticles.  Polymer nanoparticles were 
suspended in DI water at a concentration of 5 mg/ml.  Gold nanorods were used as 
received at a concentration of approximately 2 mg/ml.  In a typical reaction 100 μl of 
polymer nanoparticle stock solution was added to 2.2 ml DI water.  A 0.5 mg weight of 
EDC was added to the solution and it was mixed on a rotary mixer for 15 minutes.  A  
volume of 250 μl of gold nanorod solution was added to the mixture and stirred 
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overnight.  Particles were dialyzed against DI water for 2 days with water changed twice 
daily.   
5.2.2 UCST Composite Nanoparticle Synthesis 
Acrylic acid (AA, inhibited with 200 ppm hydroquinone monomethyl ether), N,N’-
methylenebisacrylamide (MBAAm), polyethylene glycol laurylether (Brij 30), 
cyclohexane, and sodium bis(2-ethylhexyl) sulfosuccinate (AOT) were obtained from 
Sigma Aldrich (Milwaukee, WI),  acrylamide (AAm) and lauroyl peroxide were obtained 
from Fisher Scientific (Hampton, NH).  Gold nanorods with Amine-terminated PEG 
chains, N-therapy amine-polymer gold nanorods, were obtained from Nanopartz 
(Loveland, CO).All materials were used as received. 
First, the IPN 50/50 PAAm/PAA polymer nanoparticles were synthesized using a 
two-step inverse (water-in-oil) microemulsion free radical polymerization.  The inverse 
emulsion solution consists of a cyclohexane continuous phase, surfactants, and an 
aqueous phase split into two separate premixes that are reacted consecutively, 
containing monomer, initiator, and water. The only difference in these two premixes 
was that one contains only AAm monomer and the other only AA monomer. 
A typical polymerization medium consisted of 81% cyclohexane oil phase, 13% 
surfactants, and 6% total aqueous phase by weight.  The surfactant mixture was a 50:50 
weight percent mixture of Brij 30 and AOT.  The aqueous phase typically consisted of 
approximately 80% water and 5% initiator by weight with the balance consisting of 
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monomer and crosslinker, N,N’-Methylene bisacrylamide (MBAAm), in the desired 
synthesis ratio.   
The surfactant was dissolved first in cyclohexane.  AAm monomer along with 
MBAAm crosslinker was dissolved in the separate water phase.  The first premixed 
aqueous phase containing AAm monomer was added to the cyclohexane and the 
mixture of the two phases along with surfactant was homogenized at 24,000 RPM for 5 
minutes.  The reaction flask was then purged with nitrogen for 30 minutes to remove 
oxygen from the system. 
An oil bath was prepared at 60 °C .  The reaction was initiated following the 
purge by immersion in the oil bath to heat to 60 °C.  After reaction for 2 hours, the 
reaction was terminated by removal from heat and exposure to the atmosphere.  A 
second aqueous monomer phase was prepared. The second aqueous phase, consisting 
of AA and additional initiator and crosslinker, is added to the reaction flask and again 
homogenized, purged, and reacted for 2 hours at 60 °C to form a second crosslinked 
polymer network that is physically entangled with the first network, but not covalently 
attached. 
After synthesis the cyclohexane solvent was removed using rotary evaporation 
under vacuum at 40 °C.  Five successive ethanol wash cycles were used to wash 
polymer.  One wash cycle consisted of suspension of approximately 0.5 g of 
nanoparticles in 25 ml of ethanol and centrifugation at 3200 rcf.  Ethanol supernatant 
was then removed and particles resuspended in ethanol for the next wash.  After 
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ethanol washing the particles were suspended in DI water and dialyzed for 10 days using 
a 12-14,000 MWCO dialysis tubing with dialysis water being changed twice daily.  
Particle solutions were then frozen in a -80° C freezer and lyophilized until dry.  Dry 
particle solutions were resuspended in the appropriate medium or used dry as 
necessary for further analysis. 
Transmission Fourier transform infrared (FT-IR) spectrometry was performed on 
freeze dried nanogels dispersed in KBr.  KBr was dehydrated at 125 °C prior to use to 
remove water. Samples were mixed with KBr at 1-2wt% and crushed with a mortar and 
pestle.  Approximately 200mg of this powder dispersion was pressed into clear, 13 mm 
pellets using a hydraulic press and evacuable potassium bromide die. IR spectra were 
recorded using a Nicolet Magna IR-560 FTIR Spectrophotometer. The machine was 
purged with nitrogen gas for at least two hours before acquiring spectra.  Each spectrum 
was an average of 100 scans with a resolution of 4 cm-1. 
Gold nanorods were attached to the surface of the IPN nanoparticles using a 
condensation reaction to form a peptide bond.  Polymer nanoparticles were suspended 
in DI water at a concentration of 5 mg/ml.  Gold nanorods were used as received at a 
concentration of approximately 2 mg/ml.  In a typical reaction, 100 μl of polymer 
nanoparticle stock solution was added to 2.2 ml DI water.  A 0.5 mg weight of EDC was 
added to the solution and it was mixed on a rotary mixer for 15 minutes.  A volume of 
250 μl of gold nanorod solution was added to the mixture and stirred overnight.  
Particles were dialyzed against DI water for 2 days with water changed twice daily.   
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5.2.3 Composite Nanoparticle Characterization by Transmission Electron Microscopy 
Transmission electron microscopy was performed to analyze particle size, 
morphology, polydispersity, and confirm attachment of gold nanorods.  TEM samples 
were prepared by placing 5 µl of aqueous particle suspension on a formvar coated 
copper TEM grid (Electron Microscopy Sciences, Hatfield, PA).  After one minute the grid 
was blotted dry using filter paper.  Particles were imaged using a FEI Tecnai 
Transmission Electron Microscope (FEI; Hillsboro, OR) operating at 80 kv equipped with 
a top mount AMT Advantage HR 1kX1k digital camera.  Composite nanoparticles were 
viewed to analyze the extent of grafting of gold nanorods to the surface of LCST and 
UCST polymer nanoparticles. 
5.3 RESULTS AND DISCUSSION 
5.3.1 LCST Composite Nanoparticle Synthesis 
Gold nanorods were incorporated into LCST polymer nanoparticles during 
aqueous dispersion polymerization.  PNIPAAm, 90/10 P(NIPAAm-co-AAm), and 90/10 
P(NIPAAm-co-AA) were synthesized in the presence of bare gold nanorods and in each 
case a fraction of the polymer particles had entrapped gold nanorods.  Typical 
polymerizations yielded systems in which 5-10% of polymer nanoparticles contained 
gold nanorods which will be discussed in further detail in Section 4.3.3.  All three of the 
polymer nanoparticle systems were able to entrap bare gold nanorods during 
polymerizations. 
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Systems with gold nanorods grafted to the surface of LCST hydrogel 
nanoparticles were also synthesized.   In this case 90/10 P(NIPAAm-co-AA) were used so 
that carboxyl pendant groups would be available for the grafting procedure.  Gold 
nanorods were attached to the surface of the polymer nanoparticles, and surface 
coverage was shown to be controlled depending on the concentration of gold nanorods 
added during incubation with polymer nanoparticles. 
The P(NIPAAm-co-AA) FT-IR spectrum is shown in Figure 5.5.  Several important 
bands are present to identify the copolymer.  A broad band between 3100 and 3400  
cm
-1 
 is caused by O-H stretching  in the AA groups.  N-H stretching in the secondary 
amide leads to a peak at 3300 cm
-1 
.  The CO carbonyl band is a sharp beak at 1650 cm
-1 
 
because of intramolecular hydrogen bonding. The amide CO stretching band adds to the 
peak at 1650 cm
-1 
 [10]. 
5.3.2 UCST Composite Nanoparticle Synthesis 
Composites of UCST IPN nanoparticles and gold nanorods were formed by 
grafting gold nanorods to the surface of the polymer nanoparticles.  Amine 
functionalized gold nanorods were attached to the acrylic acid residues present in the  
polymer backbone using the peptide coupling reaction activated by EDC.  The surface 
coverage of the grafted nanorods on the polymer was a function of gold nanorod 
concentration incubated with the polymer nanoparticles, which will be further discussed 
in Section 4.3.4.  
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The FT-IR spectrum is displayed in Figure 5.6. The stretching of C-N, and C=O 
coupled with the bending of O-H groups leads to an absorption band centered at 1200 
cm
-1
.  Absorption bands at 1455 and 1416 cm
-1
 are caused by scissor and bending 
vibrations of CH2 and CH-CO.  The band at 1680 cm
-1
 is caused by combined stretching 
vibrations of the C=O groups of both PAAm and PAA as well as the effects of hydrogen 
bonding between the two networks.  An absorption band at 2950 cm
-1
 corresponds to 
the combined stretching of CH2 groups in both PAAm (2945 cm
-1
) and PAA (2960 cm
-1
).  




5.3.3 Composite Nanoparticle Characterization by Transmission Electron Microscopy 
Gold-polymer composites formed during the aqueous dispersion polymerization 
of LCST hydrogel nanoparticles were imaged using TEM.  Based on TEM micrographs, 
gold nanorods were entrapped in up to 10% of polymer nanoparticles during nucleation 
in dispersion polymerization.  Representative micrographs of nanoparticles synthesized 
using this method are shown in Figures 5.7 through 5.9. 
Transmission electron microscopy was used to examine the gold-polymer grafted 
nanoparticles after composite synthesis and evaluate the effectiveness of the 
procedures.  TEM samples were prepared by depositing nanoparticles on a TEM grid 
directly from aqueous suspensions.  TEM images confirm the attachment of gold 
nanorods to the surface of the temperature responsive polymer nanoparticles.  
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Representative TEM images of P(NIPAAm-co-AA) based polymer nanoparticles of several 
different magnifications are shown in Figures 5.10 through 5.12.  IPN nanoparticles are 
shown in TEM micrographs in Figures 5.13 and 5.14. 
5.4 CONCLUSIONS 
In order to formulate systems that could be used to externally trigger the release 
of a drug using NIR light, two components were necessary in the system.  First, a 
polymer nanoparticle capable of entrapping a drug and release it upon heating, and 
second a means to respond to light in a manner in which it will transmit heat to this 
polymer layer.  Gold nanorods were identified as an appropriate heating element.  In 
order for the system to be formulated the gold nanorods were incorporated into the 
polymer nanoparticle systems using two different means.  Gold nanorods were 
entrapped in PNIPAAm, P(NIPAAm-co-AAm), and P(NIPAAm-co-AA) systems during 
aqueous dispersion polymerization as confirmed by transmission electron microscopy.  
Gold nanorods were also grafted to the surface of temperature responsive 
nanoparticles following polymerization.  50/50 PAAm/PAA nanoparticles and 90/10 
P(NIPAAm-co-AA) nanoparticles were synthesized using a water-in-oil microemulsion 
polymerization and aqueous dispersion polymerization, respectively.  Amine 
functionalized gold nanorods were grafted to the surface of the nanoparticles using an 
EDC activated condensation reaction between carboxyl groups on the polymers and the 
amine groups on the nanorods.  TEM results confirmed the formation of these gold-
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polymer composite nanoparticle systems.  Measurement of the absorption spectra over 
a 600-1000 nm wavelength range further demonstrated the attachment of gold 
nanorods to the surface of LCST polymer nanoparticles.  A broadening and shifting of 
the spectrum was observed as the temperature was increased through and above the 













Figure 5.1 TEM micrograph of gold nanoshells formed from a gold coated silica particle 
with absorption centered around 800 nm.   
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Figure 5.2 TEM micrograph of gold nanorods with 4:1 aspect ratio, 40 nm in length and 




Figure 5.2 Schematic of the proposed externally-controlled therapeutic system 










Figure 5.3 Schematic of the procedure for grafting of gold nanorods to polymer 















































Figure 5.7 TEM micrograph of gold-polymer composites formed during nucleation of 







Figure 5.8 TEM micrograph of a single gold-polymer composite formed during 





Figure 5.9 TEM image of gold-polymer composites formed during nucleation process in 















Figure 5.11 TEM micrograph of gold-polymer composite with P(NIPAAm-co-AA) 





Figure 5.12 Gold-polymer composite TEM micrograph og P(NIPAAm-co-AA) 




Figure 5.13 TEM micrograph of IPN based gold-polymer composite formed by grafting 
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Chapter 6: Loading and Release Characteristics of a Model Therapeutic 
from Hydrogel Nanoparticles 
6.1 INTRODUCTION 
In order to evaluate the potential use of a nanoparticle delivery system for 
therapeutic use, laboratory tests can be conducted to measure the effectiveness of the 
system to entrap and release a compound under relevant conditions.  Small scale 
loading tests can be conducted to measure the amount of a therapeutic or model that 
can be carried by the system.  Prior to testing a therapeutic system in live animal or 
human subjects, the release characteristics can be measured at the lab bench under 
conditions to best mimic the physiological environment. 
A variety of different polymer nanoparticle systems have been developed to load 
and release therapeutics.  Biodegradable, self-assembled, and hydrogel nanoparticles 
have been used to quantify loading and release of drugs.  The loading of a therapeutic 
refers to entrapment, encapsulation, attachment, or otherwise incorporation of a 
compound of interest into the carrier system.  When discussing the loading of a 
molecule of interest in a delivery system there are two common numbers cited to 
quantify the extent of loading.  Encapsulation or entrapment efficiency (EE) which is the 
fraction of a compound that was successfully loaded in a carrier based on the amount of 







 Loading capacity provides a measure of how much of a compound is 
incorporated into a carrier with respect to the amount of carrier.  Typically described as 
a weight fraction, loading capacity is simply the weight of the compound loaded into the 
system divided by the total weight of the carrier system itself prior to the loading 
procedure.  Loading capacity is quantified using the following equation: 
WeightPolymerTotal
WeightDrugEntrapped
CapacityLoading =  
Self-assembled nanoparticles, including liposomes, micelles, and polymersomes, 
can be formed using various amphiphiles such as natural lipids or block copolymers.  
Liposomal encapsulation is a versatile method to load therapeutics, because hydrophilic 
drugs and biomolecules can be loaded in the inner aqueous void, while hydrophobic 
molecules can be entrapped in the lipid bilayer.  Liposomal delivery of 
chemotherapeutics has been established as an effective method to increase efficacy and 
decrease toxicity over free drug, evidenced by the success of liposomal doxorubicin, 
Doxil®, which has been approved for human use in cancer treatment [1].   
In addition to the lipid structures, synthetic block copolymers built with one 
hydrophilic block and one hydrophobic block have been shown to exhibit a variety of 
self-assembled structures including spherical or cylindrical micelles and vesicles with 
architectures that resemble liposomes known as polymersomes [2].  Micelles, 
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nanoparticles with a hydrophobic core and hydrophilic outer layer, self-assembled from 
amphiphilic block copolymers in aqueous media, are frequently used to entrap 
hydrophobic drugs during micelle formation.  During spontaneous micelle formation in 
an aqueous environment, hydrophobic drugs such as anticancer agents are localized in 
and around the hydrophobic core [3-6]. 
 While traditional micelle systems have been used primarily to incorporate 
hydrophobic drugs, adapted systems have been used to entrap more hydrophilic species 
such as biomolecules.  For example, drug carrier systems called polyion complex (PIC) 
micelles have been synthesized from PEG block copolymers. The PIC micelles are formed 
using block copolymers consisting of a hydrophilic block and a polyionic block.  In this 
case, electrostatic interactions between the ionic polymer and an oppositely charged 
species are a driving force for the formation of the micelles.  Poly(ethylene glycol-
grafted-chitosan), PEG-g-chitosan, block copolymers were used to entrap diammonium 
glycyrrhizinate (DG) in micelles assembled in acetate buffer after addition of TPP to 
induce chitosan aggregation [7]. 
Polymer vesicles called polymersomes or polymerosomes have been used to 
entrap a variety of therapeutics and model drugs.  [8, 9].  Recently, there has been 
interest in creating systems that are hybrid particles combining properties of liposomes 
and synthetic polymer systems for nanodelivery applications.  Several of these systems 
have been used to entrap hydrophobic cancer drugs while incorporating synthetic 
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polymers such as PEG to add stealth characteristics to the system or include targeting 
ligands in the system [10, 11]. 
Biodegradable polymers such as poly(lactic acid-co-glycolic acid)  (PLGA) are also 
of interest for nanoparticle based drug delivery systems.  A number of hydrophobic 
compounds have been loaded into PLGA degradable particles using double emulsion 
methods.  These oil-in-water emulsions have been used to load anti-cancer therapeutics 
[12-14].  In addition to hydrophobic drugs, encapsulation of water-soluble drugs and 
biomolecules, including proteins and certain chemotherapeutics, has been achieved 
with water-in-oil-in-water double emulsion techniques [15-17]. Alternatively a few other 
techniques have been used to load drugs into PLGA particles including 
nanoprecipitation, spray drying, and spray freezing into liquid [18-22].  There has also 
been some work incorporating drugs into biodegradable polyanhydride carriers on the 
nanoscale during particle formation or using double emulsion techniques such as water-
in-oil-in-water [23, 24].   
Naturally occurring biodegradable polymers have also been investigated for their 
loading and release characteristics.  For example, chitosan carriers have received 
considerable attention for delivery of nucleic acids and a number of techniques have 
been developed to synthesize chitosan nanoparticles including ionic gelation, 
precipitation, reverse micelle formation, self-assembly, and spray drying [25, 26].  In one 
study, bovine serum albumin (BSA), was loaded into chitosan nanoparticles prepared by 
two different methods using tripolyphosphate (TPP) as an ionic crosslinker either during 
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particle formation or using an incubation method where BSA was adsorbed to the 
surface of nanoparticles [27].  In another study, chitosan nanoparticles crosslinked with 
TPP were loaded with methotrexate disodium (MTX) using a post-polymerization 
incubation method.  [28].  Chitosan nanoparticles have also been formulated to deliver 
anticancer drugs using emulsion methods. For example, a water-in-oil microemulsion 
method was used to entrap a doxorubicin-dextran conjugate in chitosan nanoparticles 
having a hydrodynamic diameter of 100 nm [29].   
The anionic biopolymer alginate has also been explored for its drug loading and 
release character.  Most often calcium chloride is added to a solution of alginate to 
induce ionic crosslinking, resulting in micro- and nanoparticle polymer networks. In one 
case, alginate gelation with calcium ions followed by coating with chitosan produced 
nanoparticles intended for oral insulin delivery applicationsIsoniazid, rifampicin, and 
pyrazinamide were encapsulated in alginate particles using a cation gelation method in 
an effort to design aerosolized nanoparticles for treatment of tuberculosis.  Calcium 
chloride was added to sodium alginate solution containing varying amounts of the three 
drugs to induce the gelation and encapsulation of the drug [30]. 
While most biodegradable or self-assembled nanoparticle systems are formed 
from previously synthesized polymers, hydrogel nanoparticles are most commonly 
synthesized using heterogeneous polymerization techniques.  Because the hydrogel 
nanoparticles are formed during polymerization, incorporating a therapeutic at this 
stage requires exposing the drug to polymerization conditions that could potentially 
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damage or modify the drug.  However, the porous characteristics of nanogel matrices 
allows for drug loading following polymerization by partitioning methods, which 
eliminates the need to subject the drug to harsh polymerization conditions.  In most 
situations, the drug is loaded into the nanogel by incubating the nanoparticles with the 
drug in aqueous conditions such that the particles are in their most swollen state.  After 
a period of time to allow the therapeutic to diffuse into the polymer matrix, a condition 
(most commonly pH or temperature) is altered, leading to a particle size transition to a 
more collapsed state with a smaller mesh size, physically entrapping the therapeutic in 
the polymer matrix. 
The hydrophilic nature of hydrogel systems makes them an ideal candidate for 
the loading and delivery of water soluble therapeutics, of particular interest 
biomacromolecules such as proteins or nucleic acids.  Several nanogel systems have 
been investigated for the delivery of insulin to the small intestine.  In addition to their 
ability to entrap the water soluble insulin, some of these systems have advantageous 
pH-sensitive properties allowing them to protect insulin in the acidic environment of the 
stomach and release it in the more neutral pH of the small intestine [31, 32].  Polybasic 
nanoparticles are cationic pH responsive hydrogels. Insulin as a model drug was added 
to a solution of the nanogels and the pH was adjusted to 6.5 to swell the nanoparticles.  
After a loading period the pH was raised quickly to 7.4 to collapse the particles and 
entrap the loaded protein.  Encapsulation efficiencies were measured up to 92% for 
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insulin in PDGP particles with low crosslinking densities when equal weights of particles 
and protein were added to the loading solution [33].   
While most hydrogel nanodelivery systems have been used to entrap hydrophilic 
molecules, recent work on modified hydrogels has demonstrated the potential to load 
hydrophobic drugs as well.  In order to do so, the hydrophobicity of the nanogels has 
been increased through the incorporation of amphiphiles into the hydrogel matrix.  An 
acrylated PEG-PPG-PEG triblock copolymer with both hydrophobic and hydrophilic 
groups was used to synthesize crosslinked nanoparticles via an inverse microemulsion 
using a PEG crosslinker.  These nanogels were then loaded with doxorubicin [34].  
Temperature responsive nanoparticles have also been used to entrap hydrophobic 
drugs.  PNIPAAm and P(NIPAAm-co-AA) nanoparticles were loaded with 5-fluorouracil 
and release was shown to be a function of pH and temperature [35].   
The nanogel systems that have been developed for this thesis were analyzed to 
investigate their loading and release characteristics.  The systems are of interest for 
their ability to load and release anticancer therapeutics.  Because of the intended 
application for breast cancer treatment chemotherapeutics that are highly used in 
breast cancer treatment, but have significant adverse health effects are of interest for 
loading into these externally controlled release systems.  Doxorubicin was identified as a 
specific compound of interest because of its frequent treatment usage but significant 
number of adverse effects such as cardiotoxixity, nausea, vomiting, hair loss, and 
immunosuppression [36]. 
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Loading of a model therapeutic, fluorescein, was quantified.  Fluorescein was 
chosen as the molecule of interest because it is similar in size, structure, and 
hydrophobicity to the chemotherapeutic doxorubicin.  Fluorescein is much less 
expensive to work with, is easily quantified using fluorescence spectroscopy and is safer 
to work with than chemotherapeutics such as doxorubicin.  The model therapeutic was 
loaded into nanoparticles using equilibrium partitioning methods following 
polymerization.  Loading capacity and entrapment efficiency were quantified for 
nanoparticles synthesized using several different crosslinking ratios.  Release from the 
nanoparticles was quantified in phosphate buffered saline (PBS) buffer to simulate 
conditions in the bloodstream. 
6.2 MATERIALS AND METHODS 
6.2.1 Hydrogel Nanoparticle Synthesis 
Acrylic acid (AA, inhibited with 200 ppm hydroquinone monomethyl ether), N-
Isopropylacrylamide (NIPAAm), and sodium dodecyl sulfate (SDS) were obtained from 
Sigma Aldrich (Milwaukee, WI),  acrylamide (AAm) and ammonium persulfate (APS) 
were obtained from Fisher Scientific (Hampton, NH).  Acrylic acid was purified using 
vacuum distillation.  All other materials were used as received. 
In order to quantify loading and release of the carrier systems nanogels were 
first synthesized using an aqueous dispersion polymerization. Crosslinked 90/10 
P(NIPAAm-co-AA) nanoparticles were used because of the shown efficacy in forming 
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gold-polymer composites as described in Chapter 3.  Crosslinking molar feed ratios were 
also varied from 1-10 % and polymer nanoparticles were synthesized containing feed 
ratios of 1, 5, and 10 mol %. 
To synthesize LCST polymers monomer, crosslinker, N,N’-Methylene 
bisacrylamide, and a stabilizer, SDS, were added to a 100 ml aqueous phase in a 250 ml 
round bottomed flask at a total monomer concentration of 5.5 g/L and a typical 
stabilizer concentration of 0.3 g/L.  The monomers and stabilizer were first dissolved in 
the aqueous medium.  Next, the aqueous reaction solution was purged with nitrogen to 
remove oxygen from the reaction flask.  A 70 °C oil bath was prepared and the purged 
reaction flask was submerged in the oil bath.  An aqueous solution of the free radical 
initiator, APS, was injected into the reaction flask to initiate reaction.  Reaction was 
allowed to proceed for at least two hours.  After completion, the reaction flask is 
opened to the air and removed from the heat source. 
The resulting nanoparticle suspension was dialyzed against DI water for 10 days 
using a 12-14,000 MWCO dialysis tubing.  Dialysis water was changed twice daily.  
Particle solutions were then frozen in a -80° C freezer and lyophilized until dry.  Dry 
particle solutions were resuspended in distilled and deionized water (ddH2O) for use in 
model compound loading studies or in the appropriate medium for other analysis and 
characterization. 
Several techniques were used to confirm synthesis of the polymer nanoparticles 
before using them for loading and release studies.  Dynamic light scattering (DLS) was 
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used to measure the overall size distributions of the hydrogel nanoparticles solution and 
to quantify polydispersity. Transmission electron microscopy (TEM) was used to 
examine the particle size distribution and to confirm the average size and spherical 
nature of the nanoparticles. 
6.2.2 Loading of Fluorescein into Hydrogel Nanoparticles 
A model therapeutic was selected in order to measure the potential ability of the 
LCST nanocarriers to load an anticancer therapeutic such as doxorubicin.  Fluorescein 
was chosen for use as a model therapeutic because it is similar in size, structure, and 
hydrophobicity to the chemotherapeutic doxorubicin.  Fluorescein was purchased from 
Sigma-Aldrich (Milwaukee, WI) and used as received.  Using fluorescein as a model 
therapeutic has several advantages over using doxorubicin in the loading studies. 
Doxorubicin and other anticancer agents are expensive to work with in comparison to 
fluorescein.  Fluorescein is also easily quantified using fluorescence spectroscopy and is 
safer to work with than chemotherapeutics such as doxorubicin. 
The model compound was loaded into the polymer nanoparticles using 
equilibrium partitioning methods with considerations made for the hydrophobic model 
and the temperature responsive polymer nanoparticles.  Fluorescein was loaded into 
swollen P(NIPAAm-co-AA) nanoparticles at several crosslinking densities in a 
water/acetone mixture with loading proceeding with the vessel open to air over a 
period of time where the acetone was allowed to evaporate. 
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In each study, a polymer nanoparticle suspension was first prepared by adding 
100 mg of dried P(NIPAAm-co-AA) particles.  The particles were added to each of three 
separate 40 ml centrifuge tubes containing 10 ml of ddH2O.  Separately, 15 mg of 
fluorescein was dissolved into three different 5 ml aliquots of acetone.  The three 
fluorescein solutions were added to the centrifuge tubes containing the aqueous 
nanoparticle dispersions.  The drug-polymer mixtures were stirred in the dark 
uncovered for 36 h as the acetone was allowed to evaporate. 
Following the 36 h loading period, samples were centrifuged at 2000 rcf and the 
supernatant containing the loaded nanoparticles was removed from the fluorescein 
pellet.  The pelleted fluorescein samples were dried in a vacuum oven at 40 °C and then 
resuspended in enough PBS to solubilize the fluorescein for quantification.  A 350 µl 
sample was collected from the supernatant solution and polymer nanoparticles were 
filtered out to quantify the amount of fluorescein remaining in solution.  Anotop anodisc 
aluminum oxide based syringe filters with a 100 nm pore size (Whatman, Piscataway, 
NJ) were used to filter out the polymer nanoparticles. 
Fluorescence spectroscopy was used at an excitation wavelength of 485 nm and 
emission of 528 nm to quantify the samples (Bio-Tek, Synergy HT, Winooski, VT).  100 µl 
samples in triplicate were used to measure the amount of fluorescein in the 
resuspended dry particles and the free solution.  A fluorescein standard curve was 
prepared in PBS and samples were read in a 96 well plate for fluorescence.  Based on 
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the total amount of fluorescein in the pellet and in the free supernatant solution the 
amount of fluorescein loaded into polymer nanoparticles was calculated. 
Loaded P(NIPAAm-co-AA) nanoparticles were dialyzed against ddH2O for 24 
hours to remove free fluorescein in the solution. The particle solution was then 
removed from the dialysis bag, placed in a 40 ml centrifuge tube and then frozen in 
liquid nitrogen.  Nanoparticles were stored in a -80 °C freezer and then lyophilized just 
prior to use in fluorescein release studies. 
6.2.3 Release of Fluorescein from Hydrogel Nanoparticles 
After loading of polymer nanoparticles with the model therapeutic fluorescein, 
release was characterized over a period of 48 hours.  The studies were performed at 
physiological conditions in PBS, 37 °C and 7.4 pH. All experiments were done using 
freeze-dried P(NIPAAm-co-AA) nanoparticles of either 1, 5, 10 mol % crosslinking that 
had previously been loaded with the model therapeutic.  Particles were taken directly 
from the lyophilizer, weighed out as necessary, and taken directly to the release 
medium for the study to ensure maximum dryness.  All release studies were performed 
in triplicate using three separate release vessels.   
After removing loaded nanoparticles from the lyophilizer three 30 mg dry 
samples were prepared from the 100 mg of loaded nanoparticles that had been 
prepared during the corresponding loading study.  Three release vessels were prepared 
with 400 ml of PBS solution at a pH of 7.4 in each.  Each release vessel was brought to 
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temperature equilibrium in a water bath at 37 °C while continuously stirred.  Next, 30 
mg of the dried, fluorescein loaded nanoparticles was added to each of the release 
volumes.  Samples of 350 µl were withdrawn from the solution at set time points over a 
48 h time period and replaced with fresh buffer.  After withdrawal of each sample it was 
immediately filtered using an Anotop syringe filter made of an aluminum oxide 
membrane with a pore size of 100 nm.  Filtration collected the polymer particles while 
allowing free fluorescein to pass through the filter. 
Fluorescence spectroscopy was used at an excitation wavelength of 485 nm and 
emission of 528 nm to quantify the samples.  Volumes of 100 µl in triplicate were used 
to measure the amount of free fluorescein in the release media.  A fluorescein standard 
curve was prepared in PBS and samples were read in a 96 well plate for fluorescence.  
The total amount of release of fluorescein into free solution was calculated based on the 
measured fluorescein concentration.  
6.3 RESULTS AND DISCUSSION 
6.3.1 Hydrogel Nanoparticle Synthesis 
Dispersion polymerization was used to successfully synthesize P(NIPAAm-co-AA) 
nanoparticles with molar extents of crosslinking of 1%, 5%, 10%.  A TEM micrograph of 
P(NIPAAm-co-AA) particles is shown in Figure 6.1.   
Crosslinking ratio is an important parameter when considering a LCST hydrogel 
delivery system.  The crosslinking ratio affects the mesh size of the polymer which must 
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be small enough to entrap and protect the therapeutic at 37 °C, but such that there is 
release when the polymer shrinks and squeezes out the drug.  Crosslinking also affects 
the size of the nanoparticle and swelling behavior which is discussed in detail in section 
6.3.3.  More highly crosslinked polymers have more tightly bound networks and a 
smaller relative mesh size.  Typically lightly crosslinked polymers are necessary to entrap 
larger therapeutics such as proteins while highly crosslinked materials more effectively 
entrap small molecular weight drugs, with medium sized drugs such as small proteins or 
peptides entrapped best at intermediate crosslinking ratios. 
In this case polymer nanoparticles were synthesized at several crosslinking ratios 
including the relatively high 5 and 10 % molar crosslinking in an effort to most 
effectively entrap the small molecular weight fluorescein, which is a good model for the 
anticancer drug doxorubicin.  Polymers that are more highly crosslinked than 10 % show 
minimum amounts of temperature-sensitive swelling behavior as shown in Chapter 4 
that would render them ineffective in temperature triggered delivery systems.   
The polymer nanoparticles that were synthesized include a 10 % molar ratio of 
acrylic acid for two reasons.  First, the addition of the more hydrophilic monomer to the 
polymer shifts the transition swelling region into a relevant temperature range centered 
at approximately 40 °C.  The presence of the acrylic acid also allows for the grafting of 
gold nanorods to the surface of the particles as described in Chapter 5.  The crosslinking 
ratios that were studied were high enough to entrap a therapeutic, but also low enough 
such that the temperature responsive swelling is significant.  In short, these systems 
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were successfully synthesized to best model systems for analysis as effective externally-
controlled delivery systems.  
6.3.2 Loading of Fluorescein into Hydrogel Nanoparticles 
Many hydrogel systems have been used to load hydrophilic molecules such as 
proteins, while results for loading small molecular weight hydrophobic drugs in hydrogel 
carriers are far less prevalent.  The PNIPAAm based systems have shown potential as 
nanogel systems for loading of hydrophobic drugs because the structure of the polymer 
includes hydrophobic domains due to the isopropyl groups present in the pendant 
groups of P(NIPAAm-co-AA).   
The trend of entrapment efficiency as a function of nanoparticle crosslinking 
ratio is shown in Figure 6.2.  Loading capacity in relation to the crosslinking ratio of the 
nanoparticle carriers is shown in Figure 6.3.  Based on the data it is clear that the ability 
of the polymer carriers to entrap fluorescein increases at higher crosslinking ratios as 
expected due to the small molecular weight and size of the model therapeutic 
compound.  The highly crosslinked (10 mol %) polymer was able to entrap the maximum 
amount of fluorescein with an overall entrapment efficiency of 80.0% and a loading 
capacity of 12.0%. Table 6.1 summarizes the overall loading characteristics for all of the 
P(NIPAAm-co-AA) hydrogel nanoparticle systems including their respective entrapment 
efficiencies and loading capacities.  
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6.3.3 Release of Fluorescein from Hydrogel Nanoparticles 
Release of fluorescein from the polymer nanoparticles was characterized over a 
period of 48 hours.  The studies were performed in PBS at physiological pH and 
temperature to mimic conditions present in the body.  The purpose of these studies was 
to show that release at physiological conditions would occur over a long period (on the 
order of hours or days) so that an externally controlled release could be triggered in the 
first hour or two of administration. 
The release of fluorescein from the materials was successfully measured using 
fluorescence spectroscopy on a UV-VIS-NIR plate spectrophotometer.  Release studies 
performed in triplicate for each polymer show sustained release of the drug from the 
nanoparticles.  Release measurements shown as a fraction of the total amount of 
fluorescein loaded into the polymers are shown in Figure 6.4 for each of the three 
differently crosslinked polymers. 
All of the polymer systems showed that total release occurred over a time period 
in excess of 12 h which makes them potential candidates for the desired types of drug 
release systems.  The more highly crosslinked systems protected the drug inside the 
particle for longer periods of time.  The entire amount of fluorescein was released from 
the 1 % crosslinked materials within 24 hours, while the 10 % crosslinked polymer 
showed that full release of the entrapped fluorescein was not achieved until over 48 
hours had elapsed.  The 5 % crosslinked system released all of the entrapped model 
therapeutic over a 24 hour period. 
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Overall 10 % crosslinked 90/10 P(NIPAAm-co-AA) demonstrated the best ability 
to entrap a high amount of fluorescein and protect it from release for the longest period 
of time. Additionally, these particles still demonstrate an overall temperature-sensitive 
volume swelling ratio over 5.  Because of the combination of an ability to load a high 
level of drug, protect it for significant amount of time, and exhibit temperature-
responsive swelling this material is a strong candidate for development of a nanoscale 
externally-controlled release system.  
6.4 CONCLUSIONS 
The capability of temperature-responsive nanoparticle systems to entrap and 
release a compound of interest was investigated.  LCST nanocarriers were first 
synthesized using aqueous dispersion polymerization methods.  The hydrogel 
nanoparticles were synthesized at varying crosslinking ratios including 1, 5, and 10 mol 
%.  A model therapeutic, fluorescein, was selected to mimic anticancer therapeutics, 
specifically doxorubicin.  Fluorescein has a similar molecular weight, structural 
character, and hydrophobicity to doxorubicin.   
Experiments were performed in the laboratory to measure the entrapment 
efficiency and loading capacity of the polymer nanocarriers.  These parameters that 
quantify loading increased in polymer systems as the amount of crosslinker present in 
the polymer system increased.  Because fluorescein is a small molecule, maximum 
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loading was achieved in very highly crosslinked systems where the polymer hydrogel 
network is tightly structured and mesh size is at a minimum. 
In order to mimic physiological conditions, release studies were performed in 
PBS buffer at 37 °C.  Samples were collected to measure release of fluorescein into the 
PBS medium using fluorescence spectroscopy after filtration of particles out of the 
sample.  Results displayed a release curve that occurred over a period of hours or days.  
The results demonstrated that at constant temperature release from the systems is slow 
enough that release could be triggered in the nanocarriers using laser light over shorter 
time periods before the entire payload naturally diffused out of the system.  The 
systems show potential for use as externally controlled polymer nanoparticle 
therapeutic carriers. 
Polymer nanoparticles formed using 10 % crosslinked 90/10 P(NIPAAm-co-AA) 
showed the highest potential for carrying and releasing a hydrophobic anticancer drug 
for the described externally triggered application.  These materials entrapped the 
highest amount of the model therapeutic and best protected the compound from 
release at constant physiological temperature and pH.   Because of the positive results 
from the loading and release studies along with their ability to exhibit temperature-
responsive swelling behavior this material is a strong candidate for development of 





Percent Crosslinker Encapsulation Efficiency Loading Capacity 
10% 80.0 ± 5.77 12.0 ± 0.86 
5% 70.4 ± 4.85 10.6 ± 0.73 
1% 52.2 ± 6.22 7.83 ± 0.93 
Table 6.1 Encapsulation efficiencies and loading capacities for fluorescein loaded into 





















































Figure 6.2 Entrapment efficiency of fluorescein loaded in P(NIPAAm-co-AA) hydrogel 




































Figure 6.3 Loading Capacity of fluorescein in P(NIPAAm-co-AA) hydrogel nanoparticles 















































Figure 6.4 Measurement of release of a model therapeutic, fluorescein, from nanogels 
at 37 °C over a 48 h period.  Release is quantified as a percentage of total 
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Chapter 7: Characterization of Externally Triggered Systems, Light 
Responsive Behavior, Cytocompatibility, and Medical Imaging 
7.1 INTRODUCTION 
 Light in the near-infrared region (NIR) is of particular interest for use in various 
in vivo applications because it can penetrate through tissue.  The region of light from 
approximately 650-900 nm has a maximum penetration depth because components of 
tissue that absorb in the visible-IR range such as water and hemoglobin have minimum 
absorptions at these wavelengths.  NIR light has been shown to penetrate at least 10 cm 
through breast tissue and about 4 cm through muscle tissue using an FDA Class 1, 
microwatt laser and while light has been shown to travel up to 7 cm through muscle 
using a higher Class 3 laser source [1-2].  Because of these properties the use of NIR light 
has been investigated for use in a number of biomedical applications. 
Externally-triggered systems such as those described in this thesis have been 
developed that use light in the NIR region as a trigger for drug release or other 
functions.  Past systems have been developed to control the release of a therapeteutic 
using light.  In one case, gold nanoshells have been incorporated into poly(N-
isoproplyacrylamide-co-acrylamide), P(NIPAAm-co-AAm), films or disks.  Upon exposure 
to certain wavelengths of light, gold nanoshells heat the polymer and trigger a negative 
swelling transition.  This behavior has been used to externally control the opening and 
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closing of a microvalve and to trigger pulsatile release of insulin from a polymer loaded 
film [3, 4].  
A number of medical imaging techniques have also been developed to take 
advantage of the penetration depths of NIR light. Reflectance imaging, multi-spectral 
imaging and fluorescence-mediated molecular tomography (FMT) have been used to 
image tissues using NIR emitting fluorochromes [5].  Several types of cyanine dyes such 
as indocyanine green have been used as contrast agent for fluorescent imaging 
techniques because they have excitation and emission maxima in the NIR range [6].  
These molecules can be coupled to targeting ligands to image tissues of interest.   
Gold nanorods are a versatile contast agent that have been used in a number of 
medical imaging techniques and have certain advantages over other contrast agents 
used in NIR based imaging modalities.  Gold nanorods have much larger cross-sections 
of absorption than molecules such as dyes and fluorophores, and the occurrence of 
optical fatigue is much lower in nanorods than other contrast agents.  Gold nanorods 
have been investigated for use in two-photon luminescence, optical coherence 
tomography, photacoustic imaging and darkfield microscopy. 
In photoacoustic imaging contrast agent that absorbs nanopulsed light 
undergoes thermoelastic expansion in response to the pulsed laser light.  A temperature 
rise associated with the excitation from the nanopulsed light leads to thermal 
expansion.  This pulsed expansion produces ultrasonic waves that are detected by the 
transducer.  The detected pattern can be used to reconstruct an image of the area of 
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interest.  A number of materials have been used as contrast agents for photoacoustic 
imaging. 
Single-walled carbon nanotubes have been used as a contrast agent to image 
tumors [7].  The targeted carbon nanotubes were administered intravenously to mice 
with tumors and a photoacoustic signal was observed at the tumor that was 8 times 
stronger than the signal from nontargeted carbon nanotubes. 
Gold nanoparticles, nanoshells, nanocages, and nanorods have all been used as 
contrast agents to create a photoacoustic signal when irradiated with short pulses of 
light [8-12].  Silver nanosystems have also been used as a contrast agent for 
photoacoustic imaging [13].  In another system gold coated ferromagnetic cobalt 
nanoparticles were shown to be an effective contrast agent [14]. 
In vitro tests have been performed to evaluate the cytocompatibility of the 
polymer nanoparticle and composite nanoparticle systems. These studies were 
performed using NIH/3T3 mouse fibroblasts as a cell model to measure the 
cytocompatibility of the nanoparticle systems with normal cell tissue.  Cellular 
proliferation in the presence of various nanoparticle was quantified using a standard 
MTS assay which measures dehydrogenase enzyme activity of metabolically active cells. 
The inclusion of gold nanorods in this system allows for the possibility to 
externally trigger drug delivery using NIR laser light.  Additionally, because the gold 
nanorods can act as contrast agents for several types of non-invasive medical imaging 
the systems have future potential for use as both diagnostic and therapeutic systems.  
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Demonstration of light-triggered swelling behavior of the nanoparticle systems 
demonstrates the potential for triggering of drug release.  Basic photoacoustic imaging 
trials show the potential of the system for use in medical imaging, and cell viability in 
the presence of the particles demonstrates potential for safe, in vivo use.  Overall the 
studies described in this chapter give evidence for the potential use of these systems for 
in vivo externally controlled drug delivery systems with imaging capabilities.  
7.2 MATERIALS AND METHODS 
7.2.1 Gold-Polymer Composite Synthesis 
Acrylic acid (AA, inhibited with 200 ppm hydroquinone monomethyl ether), N-
Isopropylacrylamide (NIPAAm), and sodium dodecyl sulfate (SDS) were obtained from 
Sigma Aldrich (Milwaukee, WI), acrylamide (AAm) and ammonium persulfate (APS) were 
obtained from Fisher Scientific (Hampton, NH). Bare gold nanorods and gold nanorods 
with amine-terminated PEG chains, N-therapy amine-polymer gold nanorods, were 
obtained from Nanopartz (Loveland, CO).  All materials were used as received. 
Composite systems incorporating temperature-sensitive polymers were 
synthesized using two different methods.  The first method involved dispersing gold 
nanorods in the pre-polymerization aqueous solution.  Polymerization proceeded using 
an aqueous dispersion polymerization method and gold nanorods served as nucleation 
points, entrapping them inside of polymer nanoparticles. 
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Crosslinked PNIPAAM composite nanoparticles were synthesized along with 
P(NIPAAm-co-AAm), and P(NIPAAm-co-AA) at molar crosslinking ratios of 10 %. To 
synthesize LCST composite monomer, crosslinker, N,N’-Methylene bisacrylamide, and a 
stabilizer (usually SDS) are added to a 100 ml aqueous phase in a 250 ml round 
bottomed flask at a total monomer concentration of 5.5 g/L and a typical stabilizer 
concentration of 0.3 g/L.  The monomers and stabilizer were first dissolved in the 
aqueous medium. 2 ml of gold nanorods at a concentration of were added to the 
polymerization flask at a concentration of approximately 0.2 mg/ml.  Next, the aqueous 
reaction solution was purged with nitrogen to remove oxygen from the reaction flask.  A 
70 °C oil bath was prepared and the purged reaction flask was submerged in the oil 
bath.  An aqueous solution of the free radical initiator, APS, was injected into the 
reaction flask to initiate reaction.  Reaction was allowed to proceed for at least two 
hours.  After completion, the reaction flask is opened to the air and removed from the 
heat source. 
The resulting composite nanoparticle suspension was dialyzed against DI water 
for 10 days using a 12-14,000 MWCO dialysis tubing.  Dialysis water was changed twice 
daily.  Particle solutions were then frozen in a -80° C freezer and lyophilized until dry.  
Dry particle solutions were resuspended in the appropriate medium or used dry as 
necessary for further analysis. 
The second method to synthesize PNIPAAm based gold-polymer systems 
consisted of grafting gold nanorods to the surface of the polymer nanoparticles.  First 
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P(NIPAAm-co-AA) with 10 mol % crosslinking were synthesized using aqueous dispersion 
polymerization as previously described.  Gold nanorods were received functionalized 
with a PEG chain with a primary amine termination.  The attachment of the PEG chain to 
the gold nanorods is achieved by reacting a heterobifunctional PEG molecule with a thiol 
group on one end the amine on the other with the gold.  
A condensation reaction was used to form a peptide bond grafting the gold 
nanorods to the surface of the polymer nanoparticles.  Polymer nanoparticles were 
suspended in DI water at a concentration of 5 mg/ml.  Gold nanorods were used as 
received at a concentration of approximately 2 mg/ml.  In a typical reaction 100 μl of 
polymer nanoparticle stock solution was added to 2.2 ml DI water.  A 0.5 mg weight of 
EDC was added to the solution and it was mixed on a rotary mixer for 15 minutes.  250 
μl of gold nanorod solution was added to the mixture and stirred overnight.  Particles 
were dialyzed against DI water for 2 days with water changed twice daily. 
7.2.2 Light-responsive Swelling Behavior  
Gold-polymer composite nanoparticles were characterized for their swelling 
behavior in response to exposure to NIR light using dynamic light scattering (DLS, 
ZetaPlus, Brookhaven, Holtsville, NY).  The hydrodynamic diameter of the particles was 
measured in solution using the DLS operating at 90˚ scattering angle with a 635 nm 35 
mW diode laser source.   
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Composite nanoparticle samples were suspended in PBS buffer at a pH of 7.4.  
Concentration of the particle solution was adjusted as necessary to achieve a photon 
count rate of approximately 300,000 counts per second.  A continuous wavelength laser 
with wavelength centered around 808 nm was used to illuminate the particles in buffer.  
The laser was set up at a 90˚ angle above the detector pointing down into the cuvette 
holding the particles. 
Measurement of the hydrodynamic diameter was collected with the laser light 
alternately turned on and off.  Each measurement was collected over a 2 minute time 
period.  The light was cycled on or off after every 2 measurement periods for a total of 
10 measurement runs.  The diameter was measured with no laser exposure for the first 
4 minutes (2 measurement runs) then turned on for the next 4 minutes, and repeatedly 
cycled in that manner for the duration of the 10 run sequence.   
7.2.3 Cytocompatibility 
In vitro tests have been performed to evaluate the cytocompatibility of the 
polymer nanoparticle and composite nanoparticle systems. These studies were 
performed using NIH/3T3 mouse fibroblasts as a cell model to measure the 
cytocompatibility of the nanoparticle systems with normal cell tissue.  Cellular 
proliferation in the presence of various nanoparticle was quantified using a standard 
MTS assay which measures dehydrogenase enzyme activity of metabolically active cells. 
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The NIH/3T3 cells were maintained in DMEM with 4 mM glutamine, 4.5 g/L 
glucose, and 10% bovine calf serum. The cells were incubated in a humidified 
environment with 5% carbon dioxide until ready for use.  In preparation for 
cytocompatibility studies, cells were seeded in 96-well plates at a density of 3000 
cells/cm
2
.  Cells were grown in the wells until they reached at least 95% confluence. 
When the cells were ready for the viability studies, 200 µl of fresh media was 
placed in each well and the plate was incubated for 1 h.  Several concentrations were 
prepared using dry P(NIPAAm-co-AA) polymer nanoparticles and gold polymer 
composites in PBS buffer solution.  A 50 µl volume of each particle solution was added 
to each well in the 96-well plate.  The plate was incubated for a 2 h period in a 5% CO2 
environment. 
After the 2 h incubation period, the media was removed from each well and 
replaced with MTS assay solution (CellTiter 96 AQueous, Promega) in PBS.  A 90 minute 
incubation period in the assay solution followed.  The absorbance was then measured 
using using a microplate reader (Synergy HT, BioTek Instruments, Inc., Winooski, VT) at 
490 nm. 
7.2.4 Photoacoustic Imaging 
Studies were performed to demonstrate the potential for these systems to be 
used as contrast agents for photoacoustic imaging.  P(NIPAAm-co-AA) nanoparticles 
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were first grafted with gold nanorods as previously described.  Next samples of the gold-
polymer composites were prepared in PBS solution. 
A nanopulsed laser operating at 775 nm and 5 mJ/cm
2 
was used to trigger the 
thermoelastic expansion in the gold nanorods that leads to the photoacoustic signal.  
After exposure to a nanopulsed laser a signal was detected from an ultrasound 
transducer.  Nanoparticles were loaded into a capillary that was exposed to the 
nanopulsed laser source and an ultrasound transducer was situated above the capillary 
which was temperature controlled.  Measurements were collected over a temperature 
range between 30 and 50 °C. 
7.3 RESULTS AND DISCUSSION 
7.3.1 Gold-Polymer Composite Synthesis 
Gold nanorods were incorporated into LCST polymer nanoparticles during 
aqueous dispersion polymerization.  PNIPAAm, 90/10 P(NIPAAm-co-AAm), and 90/10 
P(NIPAAm-co-AA) were synthesized in the presence of bare gold nanorods and in each 
case a fraction of the polymer particles entrapped gold nanorods.  Typical 
polymerizations yielded systems in which 5-10% of polymer nanoparticles contained 
gold nanorods which will be discussed in further detail in section 4.3.3.  All three of the 
polymer nanoparticle systems were able to entrap bare gold nanorods during 
polymerizations. 
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Systems with gold nanorods grafted to the surface of LCST hydrogel 
nanoparticles were also synthesized.   In this case 90/10 P(NIPAAm-co-AA) were used so 
that carboxyl pendant groups would be available for the grafting procedure.  Gold 
nanorods were attached to the surface of the polymer nanoparticles and surface 
coverage was shown to be controlled depending on the concentration of gold nanorods 
added during incubation with polymer nanoparticles. 
7.3.2 Light-responsive Swelling Behavior 
Dynamic light scattering was used to measure the hydrodynamic diameter of the 
particles before, during, and after exposure to a NIR light source.  Hydrodynamic 
diameter of the particle solution was measured at 37 °C prior to exposure to light source 
and shown to be consistent with previous swelling results.  A reversible swelling 
behavior was observed in response to light exposure as shown in Figure 7.1.  
During periods of time where the light was off the particles were in the normal 
swollen state expected at 37 °C, but during periods of time where the laser was turned 
on the particles collapsed into a less swollen state demonstrating the potential to 
squeeze out an entrapped drug.  This change was reversible.  When the laser was turned 
off the particles swelled back to their initial state.  All of the swelling events occurred 
rapidly, but because each measurement is taken over a period of 2 minutes it is not 
possible to conclude how quickly swelling took place other than to say it occurred in less 
than 2 minutes.     
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7.3.3 Cytocompatibility 
An NIH/3T3 mouse fibroblast model was used to demonstrate cell viability in the 
presence of nanoparticle systems.  The MTS assays were used to quantify viability in 96-
well plates.  Figure 7.2 displays the results of cell viability for P(NIPAAm-co-AA) polymer 
systems at several concentrations.  Proliferation measurements are shown as a 
percentage of the control systems.  At all concentrations there was not significant cell 
death caused by the presence of the polymer nanoparticles.  All of the measurements 
showed that at least 80% of the cells remained viable.  Concentrations all the way up to 
4 mg/ml were studied and shown to have minimal impact on cell survival.   
All systems showed high cellular compatibility.  Cell proliferation in the studies 
does decrease slightly as the concentration of the gold-polymer nanoparticles is 
increased.  Results as quantified using the MTS assay are shown for gold-polymer 
systems in Figure 7.3.   All of the samples had cell viabilities above 80%.  The lower 
concentrations that were tested, up to 250 μg/ml did not show statistically significant 
cell death compared to control.  At a concentration of 500 μg/ml there was slightly 
lower cell viability, but still over 80% cell viability. 
7.3.4 Photoacoustic Imaging 
Gold-polymer composite systems were shown to have potential for use as 
contrast agents in medical imaging such as photoacoustic imaging.  After exposure to a 
nanopulsed laser a signal was detected from an ultrasound transducer.  Nanoparticles 
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were loaded into a capillary that was exposed to the nanopulsed laser source and an 
ultrasound transducer was situated above the capillary which was temperature 
controlled. 
The results in Figure 7.4 demonstrate the magnitude of the photoacoustic signal 
detected by the ultrasound transducer at a range of temperatures.  A photoacoustic 
signal was dectected over a range of temperatures from 35 to 50 °C using 0.5 mg/ml and 
2 mg/ml concentrations of particles.  Based on this data there is potential for 
photoacoustic imaging to be used in conjuction with therapeutic delivery from these 
systems and an ultrasound transducer may be used to correlate the temperature of the 
systems in vivo.  
7.4 CONCLUSIONS 
Gold-polymer composites were synthesized in the lab for use as externally 
triggered delivery systems.  In order to demonstrate the potential of these systems for 
diagnostic and therapeutic use several proof of concept studies were performed.  The 
results of these studies can be used to conclude that the systems show potential for 
biocompatibility and safe use.  The composite systems also may be triggered to collapse 
and subsequently release a therapeutic.  Lastly, an experiment to test the photoacoustic 
signal produced by the particles demonstrates that the gold nanorods present in the 
system can be used as a contrast agent for potentially non-invasive medical imaging 
using NIR light. 
 164 
Cell proliferation studies demonstrated that the particles cause limited cell death 
in a 3T3 mouse fibroblast cell model.  Both polymer nanoparticles and gold-polymer 
systems showed high cellular compatibility that was a function of particle concentration.  
Light was used to induce a swelling response in gold-polymer composites.  Particles 
were shown to quickly collapse in response to the light and reversibly swell after the 
light was switched off. After previous results demonstrated that the particle systems 
have the ability to entrap a model therapeutic it is clear that these systems may be used 
to trigger a drug delivery response with light.  A photoacoustic signal was detected in 
response to a nanopulsed laser with NIR wavelength. The signal from these nanoparticle 
systems was shown to be a function of temperature over a relevant therapeutic range 





















































Figure 7.5 Swelling behavior of gold-polymer composites with alternating laser 
exposure.  P(NIPAAm-co-AA) polymer nanoparticles grafted with gold 














4 2 1 0.5 0.25 0.125 0.0625
Concentration of Polymer Nanoparticles (mg/ml)
 
 
Figure 7.2 Cell viability of 3T3 mouse fibroblasts as a percentage of control when 
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Figure 7.3 Cell viability of 3T3 mouse fibroblasts as a percentage of control when 

































Figure 7.4 Photoacoustic signal measured from gold-polymer composites.  Signal 
measured from P(NIPAAm-co-AA) nanoparticles grafted with gold nanorods 
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Chapter 8:  Conclusions  
Externally-triggered therapeutic systems are those that allow a therapeutic to be 
released from a carrier in response to some external stimulus.  In this thesis nanoscale 
externally-triggered systems were developed for use in chemotherapy for breast cancer 
treatment and medical imaging techniques.  Nanoscale systems are of interest because 
they could be administered intravenously, extend half-lives of circulation, and localize at 
a disease site because of the enhanced permeability and retention (EPR) effect. 
The proposed system uses a NIR light source as the external stimulus to trigger 
drug release.  NIR light has the ability to penetrate through tissue and is therefore an 
attractive external trigger for drug deliver.  Gold nanorods can absorb light in this region 
of interest and convert it to heat.  A temperature responsive polymer hydrogel 
nanoparticle can entrap a drug and release it in response to heating through a swelling 
transition temperature.  In this work gold nanorods were grafted to the surface of 
temperature responsive nanoparticles so that light absorbed by the gold is converted to 
heat which induces a swelling transition and associated therapeutic release from the 
polymer.  Additionally, the gold nanorods can act as a contrast agent for certain non-
invasive medical imaging techniques such as photoacoustic imaging.   
Several types of temperature responsive nanogels were synthesized for use in 
these drug delivery systems.  Particles exhibiting LCST behavior including PNIPAAm, 
P(NIPAAm-co-AAm), and P(NIPAAm-co-AA) were synthesized using an aqueous 
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dispersion polymerization.  Copolymers with varying monomer ratios were examined for 
their ability to tune the LCST of the systems, and the ability to increase the temperature 
of this transition by addition of a more hydrophilic monomer was confirmed. IPN 
nanoparticles exhibiting UCST behavior composed of equimolar networks of PAA and 
PAAm were formulated with a water-in-oil microemulsion polymerization.  The effect of 
surfactant concentration and crosslinking ratio on size and swelling behavior of the 
nanoparticles was analyzed.  Polymer size, shape, and morphology were verified using 
microscopy techniques including SEM and TEM.  The characterizations can be used to 
gain insight into the potential of these systems as nanoscale drug carriers, where the 
determination of size and swelling behavior can be used to select the appropriate 
particles for delivery of a specified therapeutic. 
In order to formulate systems that could be used to externally trigger the release 
of a drug using NIR light an additional component other than the temperature-
responsive polymer was necessary in the system.  The component must respond to light 
in a manner in which it will transmit heat to this polymer layer and trigger release of an 
entrapped therapeutic agent.  Gold nanorods were identified as an appropriate heating 
element.  In order for the system to be realized the gold nanorods were incorporated 
into the polymer nanoparticle systems using two different means.  Gold nanorods were 
entrapped in PNIPAAm, P(NIPAAM-co-AAm), and P(NIPAAm-co-AA) systems during 
aqueous dispersion polymerization as confirmed by transmission electron microscopy.  
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Gold nanorods were also grafted to the surface of temperature responsive 
nanoparticles following polymerization.  50/50 PAAm/PAA nanoparticles and 90/10 
P(NIPAAm-co-AA) nanoparticles were synthesized using water in oil microemulsion 
polymerization and aqueous dispersion polymerization respectively.  Amine 
functionalized gold nanorods were grafted to the surface of the nanoparticles using an 
EDC activated condensation reaction between carboxyl groups on the polymers and the 
amine groups on the nanorods.  TEM results confirmed the formation of these gold-
polymer composite nanoparticle systems.  Measurement of the absorption spectra over 
a 600-1000 nm wavelength range further demonstrated the attachment of gold 
nanorods to the surface of LCST polymer nanoparticles.  A broadening and shifting of 
the spectrum was observed as the temperature was increased through and above the 
LCST transition temperature. 
The capability of temperature responsive nanoparticle systems to entrap and 
release a compound of interest was investigated.  LCST nanocarriers were first 
synthesized using aqueous dispersion polymerization methods.  The hydrogel 
nanoparticles were synthesized at varying crosslinking ratios including 1, 5, and 10 mol 
%.  A model therapeutic, fluorescein, was selected to mimic anticancer therapeutics, 
specifically doxorubicin.  Fluorescein has a similar molecular weight, structural 
character, and hydrophobicity to doxorubicin.   
The entrapment efficiency and loading capacity of the polymer nanocarriers 
were measured for fluorescein, a model for chemotherapeutics.  These parameters that 
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quantify loading increased in polymer systems as the amount of crosslinker present in 
the polymer system increased.  Because fluorescein is a small molecule, maximum 
loading was achieved in very highly crosslinked systems where the polymer hydrogel 
network is tightly structured and mesh size is at a minimum. 
In order to mimic physiological conditions, release studies were performed in 
PBS buffer at 37 °C.  Samples were collected to measure release of fluorescein into the 
PBS medium using fluorescence spectroscopy after filtration of particles out of the 
sample.  Results showed a release curve that occurred over a period of hours or days 
depending on the hydrogel formulation.  The results demonstrated that release from 
the systems is slow enough at constant temperature that release could be triggered in 
the nanocarriers using laser light over shorter time periods before the entire payload 
naturally diffused out of the system.  The systems show potential for use as externally 
controlled polymer nanoparticle therapeutic carriers. 
Polymer nanoparticles formed using 10 % crosslinked 90/10 P(NIPAAm-co-AA) 
showed the highest potential for carrying and releasing a hydrophobic anticancer drug 
for the described externally triggered application.  These materials entrapped the 
highest amount of the model therapeutic and best protected the compound from 
release at constant physiological temperature and pH.   Because of the positive results 
from the loading and release studies along with their ability to exhibit temperature-
responsive swelling behavior this material is a strong candidate for development of 
nanoscale externally-controlled release systems 
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In order to demonstrate the potential of these systems for diagnostic and 
therapeutic use, several proof of concept studies were performed.  The results of these 
studies can be used to conclude that the systems show potential for biocompatibility 
and safe use.  The composite systems also may be triggered to collapse and 
subsequently release a therapeutic.  Lastly, an experiment to test the photoacoustic 
signal produced by the particles demonstrates that the gold nanorods present in the 
system can be used as a contrast agent for potentially non-invasive medical imaging 
using NIR light. 
Cell proliferation studies demonstrated that the particles cause limited cell death 
in a 3T3 mouse fibroblast cell model.  Both polymer nanoparticles and gold-polymer 
systems showed high cellular compatibility that was a function of particle concentration.  
Light was used to induce a swelling response in gold-polymer composites.  Particles 
were shown to quickly collapse in response to NIR light and reversibly swell after the 
light was switched off. After previous results demonstrated that the particle systems 
have the ability to entrap a model therapeutic it is clear that these systems may be used 
to trigger a drug delivery response with light.  A photoacoustic signal was detected in 
response to a nanopulsed laser with NIR wavelength. The signal from these nanoparticle 
systems was shown to be a function of temperature over a relevant therapeutic range 
showing the potential for the use of in vivo medical imaging techniques. 
Overall, the materials developed in this thesis show potential for use as 
externally-triggered nanoscale systems for delivery of chemotherapeutics.  Future work 
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needs to be done to optimize the systems for light-triggered delivery of a therapeutic 
agent.  Additional studies to validate the efficacy of the systems as a contrast agent for 
photoacoustic imaging could show that the systems could be effectively used to 
simultaneously image a disease site and deliver a drug.  There is also a great need for 
detailed studies on the biocompatibility and toxicity of nanoscale materials such as 
these developed for applications in drug delivery. 
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